US20090317798A1 - Analysis using microfluidic partitioning devices - Google Patents
Analysis using microfluidic partitioning devices Download PDFInfo
- Publication number
- US20090317798A1 US20090317798A1 US11/916,025 US91602506A US2009317798A1 US 20090317798 A1 US20090317798 A1 US 20090317798A1 US 91602506 A US91602506 A US 91602506A US 2009317798 A1 US2009317798 A1 US 2009317798A1
- Authority
- US
- United States
- Prior art keywords
- sample
- cells
- sub
- samples
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0874—Three dimensional network
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
- B01L2400/0655—Valves, specific forms thereof with moving parts pinch valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
Definitions
- the invention relates to methods, reagents and devices for detecting and characterizing nucleic acids, cells, and other biological samples.
- nucleic acid amplification assays and immunological assays are used for analysis of cells and nucleic acids. These assays can be used to detect or characterize nucleic acid sequences associated with particular diseases or genetic disorders, for genotyping, for gene expression analyses, to detect and identify pathogens such as viruses, bacteria and fungi), for paternity and forensic identification, and for many other purposes. However, in some applications the efficiency and sensitivity of these assays is reduced, which may render the assays useless or at minimum require that additional manipulations and/or significant amounts of expensive reagents be used.
- the invention relates to methods, reagents and devices for detection and characterization of nucleic acids, cells, and other biological samples.
- the invention provides an assay method including the following steps (a) partitioning a sample into a plurality of sub-samples, where said sample comprises a plurality of nucleic acid molecules, and where at least two sub-samples comprise at least one nucleic acid molecule; (b) providing sufficient reagents in each sub-sample to amplify a target sequence or sequences; (c) amplifying the target sequence(s) in the sub-sample(s) containing target sequence(s) thereby producing amplicons in the sub-sample; (d) distributing the amplicons into a plurality of aliquots; and, (e) for each aliquot, determining a property of amplicons in the aliquot.
- the invention provides an assay method including the following steps (a) partitioning a sample into a plurality of sub-samples, where said sample comprises a plurality of nucleic acid molecules, and where at least two sub-samples comprise at least one nucleic acid molecule; (b) providing sufficient reagents in each sub-sample to amplify at least two different target sequences; (c) amplifying target sequence(s) in at least two sub-sample(s) thereby producing amplicons in the sub-sample(s); (d) combining the amplicons from said at least two sub-samples to create an amplicon pool; (d) dividing the amplicon pool into a plurality of aliquots; and, (e) for each aliquot, determining a property of amplicons in the aliquot.
- the sample is partitioned into at least 10 4 sub-samples. In one embodiment, each subsample has a volume of less than one nanoliter.
- the nucleic acid molecules comprise DNA and/or mRNA.
- the amplification is by PCR or RT-PCR. In one embodiment, sufficient reagents are provided to amplify at least 10, 20, or 50 different target sequences, if present. In one embodiment, the amplicon pool is divided into at least 10, 20, 50 or 100 aliquiots.
- the sample contains a plurality of cells having nucleic acid molecules, and partitioning the sample involves partitioning intact cells into a plurality of sub-samples. In one embodiment, the sample contains only one cell.
- the invention provides an assay method including the following steps (a) partitioning a sample comprising a plurality of separable cells into at least 1000 separate reaction chambers in a massively partitioning device (MPD), where after partitioning at least two reaction chambers each comprise exactly one cell; (b) providing in each reaction chamber one or more reagents for determining a property or properties of a cell, where the same reagents are provided in each chamber; and (c) determining at least two different properties of a single cell in a chamber and/or determining at least one property for at least two different cells in different chambers.
- at least 99% of the reaction chambers contain zero or one cell.
- the cells are bacterial cells.
- the reagents include reagents for nucleic acid amplification.
- at least one property is the presence or absence in the cell of a nucleic acid having a specified sequence. In one embodiment, at least one property is other than the presence or absence in the cell of a nucleic acid having a specified sequence.
- the invention provides a method for amplification and detection of multiple target DNA sequences in a sample, including the following steps: (a) providing a sample containing (i) multiple target DNA sequences, (ii) a primer pair corresponding to each of said multiple target DNA sequences, each pair consisting of a first primer comprising U 1 , B 1 and F domains in the order 5′-U 1 -B 1 -F-3′ and a second primer comprising U 2 and R domains in the order 5′-U 2 -R-3′, where each pair of F and R primers is capable of annealing specifically to a different target DNA sequence under stringent annealing conditions; (iii) a universal primer pair capable of amplifying a double stranded DNA molecule with the structure
- the invention provides a microfluidic device, having (a) a first region comprising (i) a flow channel formed within an elastomeric material and having a first end and a second end in fluid communication with each other through said channel, where said channel may be branched or unbranched; (ii) an inlet for introducing a sample fluid in communication with said channel, said inlet; (iii) an outlet in communication with said flow channel; (iv) a plurality of control channels overlaying the flow channel(s), where an elastomeric membrane separates the control channels from the flow channels at each intersection, the elastomeric membrane disposed to be deflected into or withdrawn from the flow channel in response to an actuation force, and where, when the control channels are actuated the flow channel is partitioned into at least 1000 reaction chambers not in fluidic communication with each other; (b) a second region compromising a channel or chamber interposed between and in communication with said outlet in (a) and a flow channel in the third region
- FIGS. 1A and 1B show an exemplary design of a massively partitioning device (MPD) in valve off ( FIG. 1A ) and valve actuated ( FIG. 1B ) states.
- MPD massively partitioning device
- FIG. 2 shows an exemplary design of a MPD with two banks: a first bank in which nucleic acids are partitioned and amplified in individual chambers, and a second bank in which subsequent analysis of the amplicon pool occurs.
- FIGS. 3A-C are flow charts illustrating partition and analysis of nucleic acids using methods of the invention.
- FIG. 3A illustrates partition and analysis of nucleic acids in which multiple target sequences are amplified.
- FIG. 3B illustrates partition and analysis acids in which target sequences in only a single chamber are amplified.
- FIG. 3C illustrates analysis of nucleic acids of a single cell.
- FIG. 4 is a flow chart illustrating partition of cells and analysis of their properties.
- FIG. 5 is an illustration of primers used in the universal amplification method.
- elastomer has the general meaning used in the art.
- Allcock et al. Contemporary Polymer Chemistry, 2nd Ed.
- elastomeric materials exhibit elastic properties because the polymer chains readily undergo torsional motion to permit uncoiling of the backbone chains in response to a force, with the backbone chains recoiling to assume the prior shape in the absence of the force.
- elastomers deform when force is applied, but then return to their original shape when the force is removed.
- the elasticity exhibited by elastomeric materials can be characterized by a Young's modulus.
- the elastomeric materials utilized in the microfluidic devices disclosed herein typically have a Young's modulus of between about 1 Pa-1 TPa, in other instances between about 10 Pa-100 GPa, in still other instances between about 20 Pa-1 GPa, in yet other instances between about 50 Pa-10 MPa, and in certain instances between about 100 Pa-1 MPa. Elastomeric materials having a Young's modulus outside of these ranges can also be utilized depending upon the needs of a particular application.
- Microfluidic devices can be fabricated from an elastomeric polymer such as GE RTV 615 (formulation), a vinyl-silane crosslinked (type) silicone elastomer (family).
- elastomeric microfluidic systems are not limited to this one formulation, type or even this family of polymer; rather, nearly any elastomeric polymer is suitable.
- monolithic elastomeric microvalves and pumps including, for example, perfluoropolyethers, polyisoprene, polybutadiene, polychloroprene, polyisobutylene, poly(styrene-butadiene-styrene), polyurethanes, and silicones, for example, or poly(bis(fluoroalkoxy)phosphazene) (PNF, Eypel-F), poly(carborane-siloxanes) (Dexsil), poly(acrylonitrile-butadiene) (nitrile rubber), poly(1-butene), poly(chloro
- a “reagent” refers broadly to any agent used in a reaction, other than the analyte (e.g., cell or nucleic acid being analyzed).
- exemplary reagents for a nucleic acid amplification reaction include, but are not limited to, buffer, metal ions, polymerase, reverse transcriptase, primers, template nucleic acid, nucleotides, labels, dyes, nucleases and the like.
- Reagents for enzyme reactions include, for example, substrates, cofactors, buffer, metal ions, inhibitors and activators.
- Reagents for cell-based reactions include, but are not limited to, cells, cell specific dyes and ligands (e.g., agonists and antagonists) that bind to cellular receptors.
- nucleic acid include a polymeric form of nucleotides of any length, including, but not limited to, ribonucleotides or deoxyribonucleotides. There is no intended distinction in length between these terms. Further, these terms refer only to the primary structure of the molecule. Thus, in certain embodiments these terms can include triple-, double- and single-stranded DNA, as well as triple-, double- and single-stranded RNA. They also include modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide.
- nucleic acid examples include polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), any other type of polynucleotide which is an N- or C-glycoside of a purine or pyrimidine base, and other polymers containing nonnucleotidic backbones, for example, polyamide (e.g., peptide nucleic acids (PNAs)) and polymorpholino (commercially available from the Anti-Virals, Inc., Corvallis, Oreg., as Neugene) polymers, and other synthetic sequence-specific nucleic acid polymers providing that the polymers contain nucleobases in a configuration which allows for base pairing and base stacking, such as is found in DNA and RNA.
- PNAs peptide nucleic acids
- Neugene commercially available from the Anti-Virals, Inc., Corvallis, Oreg., as Neugene
- a “primer” is a single-stranded polynucleotide capable of acting as a point of initiation of template-directed DNA or RNA synthesis under appropriate conditions (i.e., in the presence of four different nucleoside triphosphates and an agent for polymerization, such as, DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature.
- the appropriate length of a primer depends on the intended use of the primer but typically is at least 7 nucleotides long and, more typically range from 10 to 30 nucleotides in length. Other primers can be somewhat longer such as 30 to 50 nucleotides long.
- primer “length” refers to the portion of an oligo- or polynucleotide that hyrbidizes to a complementary “target” sequence and primes synthesis.
- the length of F 1 might be 20 nucleotides and the combined length of U, B and F1 could be 60 nucleotides or more (typically between 30 and 100 nucleotides).
- Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.
- a primer need not reflect the exact sequence of the template but must be sufficiently complementary to hybridize with a template.
- primer site or “primer binding site” refers to the segment of the target DNA to which a primer hybridizes.
- primer pair means a set of primers including a 5′ “upstream primer” that hybridizes with the complement of the 5′ end of the DNA sequence to be amplified and a 3′ “downstream primer” that hybridizes with the 3′ end of the sequence to be amplified.
- a primer or probe anneals or hybrdizes to a complementary target sequence.
- the primer or probe may be exactly complementary to the target sequence or can be less than perfectly complementary.
- the primer has at least 65% identity to the complement of the target sequence over a region of at least 7 nucleotides, more typically over a region in the range of 10-30 nucleotides, and often over a region of at least 14-25 nucleotides, and more often has at least 75% identity, at least 85% identity or 90% identity.
- certain bases e.g., the 3′ base of a primer
- Primer and probes generally anneal to the target sequence under stringent conditions.
- Stringent annealing conditions refers to conditions in a range from about 5° C. to about 20° C. or 25° C. below the melting temperature (T m ) of the target sequence and a probe with exact or nearly exact complementarity to the target.
- T m melting temperature
- the melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half-dissociated into single strands.
- T m 81.5+0.41(% G+C), when a nucleic acid is in aqueous solution at 1 M NaCl (see e.g., Anderson and Young, Quantitative Filter Hybridization in NUCLEIC ACID HYBRIDIZATION (1985)).
- the melting temperature of a hybrid is affected by various factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, and the like), and the concentration of salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol).
- factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, and the like), and the concentration of salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol).
- a “probe” is an nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation, thus forming a duplex structure.
- the probe binds or hybridizes to a “probe binding site.”
- the probe can be labeled with a detectable label to permit facile detection of the probe, particularly once the probe has hybridized to its complementary target.
- the label attached to the probe can include any of a variety of different labels known in the art that can be detected by chemical or physical means, for example.
- Suitable labels that can be attached to probes include, but are not limited to, radioisotopes, fluorophores, chromophores, mass labels, electron dense particles, magnetic particles, spin labels, molecules that emit chemiluminescence, electrochemically active molecules, enzymes, cofactors, and enzyme substrates.
- Probes can vary significantly in size. Some probes are relatively short. Generally, probes are at least 7 to 15 nucleotides in length. Other probes are at least 20, 30 or 40 nucleotides long. Still other probes are somewhat longer, being at least 50, 60, 70, 80, 90 nucleotides long. Yet other probes are longer still, and are at least 100, 150, 200 or more nucleotides long. Probes can be of any specific length that falls within the foregoing ranges as well.
- label refers to a molecule or an aspect of a molecule that can be detected by physical, chemical, electromagnetic and other related analytical techniques.
- detectable labels include, but are not limited to, radioisotopes, fluorophores, chromophores, mass labels, electron dense particles, magnetic particles, spin labels, molecules that emit chemiluminescence, electrochemically active molecules, enzymes, cofactors, enzymes linked to nucleic acid probes and enzyme substrates.
- detectably labeled means that an agent has been conjugated with a label or that an agent has some inherent characteristic (e.g., size, shape or color) that allows it to be detected without having to be conjugated to a separate label.
- a “polymorphic marker” or “polymorphic site” is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair. Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu. The first identified allelic form is arbitrarily designated as the reference form and other allelic forms are designated as alternative or variant alleles.
- allelic form occurring most frequently in a selected population is sometimes referred to as the wildtype form. Diploid organisms may be homozygous or heterozygous for allelic forms.
- a diallelic polymorphism has two forms.
- a triallelic polymorphism has three forms.
- a “single nucleotide polymorphism” occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations).
- a single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site.
- a transition is the replacement of one purine by another purine or one pyrimidine by another pyrimidine.
- a transversion is the replacement of a purine by a pyrimidine or vice versa.
- Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele.
- haplotype refers to the designation of a set of polymorphisms or alleles of polymorphic sites within a gene of an individual.
- plurality means at least three. In general a plurality of cells, nucleic acid molecules, etc., will contain at least 10, at least about 10 2 , at least about 10 3 , or at least about 10 4 different cells, molecules, etc.
- Entities refers to a plurality of structurally similar biological molecules or structures (e.g., macromolecules such as nucleic acids, protein, carbohydrates and lipids; cells or subcellular structures or components; viruses) or nonbiological particles that are separate and distinct from each other in the sense that they can be separated into separate reaction chambers using a MPD. “Entity” refers to a single such molecule or structure.
- biological sample refers to a sample obtained from an organism or from components of an organism, such as cells, biological tissues and fluids. In some methods, the sample is from a human patient. Such samples include sputum, blood, blood cells (e.g., white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and fleural fluid, or cells therefrom.
- blood cells e.g., white cells
- tissue or fine needle biopsy samples e.g., urine, peritoneal fluid, and fleural fluid, or cells therefrom.
- the invention relates generally to analysis of macromolecules and small particles, and particularly to analysis of nucleic acids, proteins, and individual cells.
- the invention relates to analysis methods involving massive partitioning. Massive partitioning of liquid samples, i.e., dividing the sample into thousands of isolated reaction volumes, has been made possible by the development of specially designed elastomeric microfluidic devices. These devices can be referred to as “massively partitioning devices” or MPDs and are sometimes referred to as “chips” or Digital Isolation and Detection Integrated Fluidic Circuits (DID IFCs). Exemplary devices are described in McBride et al. (PCT publication WO 2004/089810, published on Oct. 21, 2004; copending, commonly assigned U.S.
- McBride et al. describes the performance of 21,000 simultaneous PCR reactions in a single microfluidic chip, in a volume of 90 picoliters per reaction and with single template molecule sensitivity.
- the invention provides new methods and devices for analysis of a sample containing nucleic acids, proteins, other biomolecules, cells, microorganisms, viruses, and other biological or nonbiological entities, in which the sample undergoes massive partitioning as part of the analysis process.
- the invention provides methods and reagents for amplification and/or detection of a nucleic acid. These methods and reagents find particular application in the analysis of nucleic acids partitioned using a MPD, but may be used in amplification-based analysis of any nucleic acid.
- Methods described in this disclosure can be, and in some cases are necessarily, carried out using an elastomeric microfluidic device.
- Methods for fabricating elastomeric microfluidic devices capable of separating molecules or cells and for carrying out reactions are known in the art (see, e.g., Unger et al., 2000, Science 288:113-116, PCT Publications WO 01/01025 and WO/02/43615; and U.S. patent application Ser. No. 10/306,798 published as Pat App. No. 20030138829 on Jul. 24, 2003).
- exemplary elastomeric massively partitioning devices (MPDs) are described in McBride et al., supra and references cited therein. Based on these and other publications, one of ordinary skill in the art guided by this disclosure will be able to practice all aspects of the inventions described herein. Accordingly, elastomeric microfluidic devices are described only briefly below.
- Elastomeric microfluidic devices are characterized in part by utilizing various components such as flow channels, control channels, valves, pumps, vias, and/or guard channels from elastomeric materials.
- FIGS. 1A and 1B show an exemplary design of a massively partitioning device.
- a “flow channel” refers generally to a flow path through which a solution can flow.
- a “blind channel” refers to a flow channel which has an entrance but not a separate exit.
- a “control channel” is a channel separated from a flow channel by an elastomeric membrane that can be deflected into or retracted from the flow channel in response to an actuation force.
- the term “valve” refers to a configuration in which a flow channel and a control channel intersect and are separated by an elastomeric membrane that can be deflected into or retracted from the flow channel in response to an actuation force.
- An “isolated reaction site” or “reaction chamber” refers to a reaction site that is not in fluid communication with other reactions sites present on the device, and which is created by the actuation of control channels in the device.
- a “via” refers to a channel formed in an elastomeric device to provide fluid access between an external port of the device and one or more flow channels. Thus, a via can serve as a sample input or output, for example.
- “Guard channels” may be included in elastomeric microfluidic devices for use in heating applications to minimize evaporation of sample from the reaction sites.
- Guard channels are channels formed within the elastomeric device through which water can be flowed to increase the water vapor pressure within the elastomeric material from which the device is formed, thereby reducing evaporation of sample from the reaction sites.
- the guard channels are similar to the control channels in that typically they are formed in a layer of elastomer that overlays the flow channels and/or reaction site. Typically, the guard channels are placed adjacent and over flow channels and reaction sites as these are the primary locations at which evaporation is the primary concern.
- Guard channels are typically formed in the elastomer utilizing the MSL techniques and/or sacrificial-layer encapsulation methods cited above.
- the solution flowed through the guard channel includes any substance that can reduce evaporation of water.
- FIGS. 1A and 1B depict an exemplary design of a partitioning microfluidic device 01 in a valve off and valve actuated state.
- a sample is injected into inlet 02 which is in communication with branched partitioning channel system 03 of the device.
- Solution flow through flow channels of the device is controlled, at least in part, with one or more control channels that are separated from the flow channel by an elastomeric membrane or segment. This membrane or segment can be deflected into or retracted from the flow channel with which a control channel is associated by applying an actuation force to the control channels so that solution flow can be entirely blocked by valves.
- Actuating the control valves creates isolated reaction chambers 05 in which individual reactions can be conducted.
- the reaction chambers can number from 10 3 to 10 5 or more be at a density of at least 100 sites/cm 2 and can range up to at least 2000, 3000, 4000 or more than 4000 sites/cm 2 .
- Very small wells or cavities can be formed within an elastomeric material to increase the volume of the reaction chamber.
- Valves can be actuated by injecting gases (e.g., air, nitrogen, and argon), liquids (e.g., water, silicon oils and other oils), solutions containing salts and/or polymers (including but not limited to polyethylene glycol, glycerol and carbohydrates), and the like into the port.
- FIG. 1 illustrates a MPD with branched flow channels
- any channel configuration (flow channel path) that can be partitioned by control channels can be used in accordance with the invention, including, for example, square, spiral or serpentine configurations.
- channels are from about 0.1 ⁇ m to about 1000 ⁇ m in any dimension, sometimes from about 0.1 to about 100 ⁇ m, and sometimes from about 0.1 to about 10 ⁇ m.
- the channels have a high aspect ratio (e.g., a height to width ratio of from about 2:1 to about 10:1) to increase channel density and/or to increase signal collection from channels containing a detectably labeled moiety.
- the channel has a columnar shape in which the dimensions of floor and ceiling are smaller that the dimensions of the walls, and a signal (e.g., fluorescence, infra red or visible radiation) is detected through the ceiling or floor.
- a dimension should be at least sufficient for passage of the cell (e.g., 2-5 times the dimension of the cell). However, for the purpose of restricting movement the dimensions can be on the order of 0.75 times the smallest dimension of the particle.
- Microfluidic manipulation and analysis of particles is also described in U.S. Patent Pub. 20040229349 entitled “Microfluidic particle-analysis systems” and incorporated herein by reference.
- Reactions e.g., nucleic acid amplification, protein binding, etc.
- PCR reactions can be initiated by heating the chambers (e.g., placing the device on a suitably programmed flat plate thermocycler.
- the results or products of the reaction can be detected using any of a number of different detection strategies. Because the MPDs are usually made of elastomeric materials that are relatively optically transparent, reactions can be readily monitored using a variety of different detection systems at essentially any location on the microfluidic device. Most typically, however, detection occurs at the reaction site itself.
- the nature of the signal to be detected will, of course, determine, to a large extent, the type of detector to be used.
- the detectors can be designed to detect a number of different signal types including, but not limited to, signals from radioisotopes, fluorophores, chromophores, electron dense particles, magnetic particles, spin labels, molecules that emit chemiluminescence, electrochemically active molecules, enzymes, cofactors, enzymes linked to nucleic acid probes and enzyme substrates.
- Illustrative detection methodologies suitable for use with the present microfluidic devices include, but are not limited to, light scattering, multichannel fluorescence detection, infra-red, UV and visible wavelength absorption, luminescence, differential reflectivity, and confocal laser scanning.
- Additional detection methods that can be used in certain application include scintillation proximity assay techniques, radiochemical detection, fluorescence polarization, fluorescence correlation spectroscopy (FCS), time-resolved energy transfer (TRET), fluorescence resonance energy transfer (FRET) and variations such as bioluminescence resonance energy transfer (BRET). Additional detection options include electrical resistance, resistivity, impedance, and voltage sensing.
- a detector can include a light source for stimulating a reporter that generates a detectable signal.
- the type of light source utilized depends in part on the nature of the reporter being activated. Suitable light sources include, but are not limited to, lasers, laser diodes and high intensity lamps. If a laser is utilized, the laser can be utilized to scan across a set of detection sections or a single detection section. Laser diodes can be microfabricated into the microfluidic device itself. Alternatively, laser diodes can be fabricated into another device that is placed adjacent to the microfluidic device being utilized to conduct a thermal cycling reaction such that the laser light from the diode is directed into the detection section.
- Detectors can be microfabricated within the microfluidic device, or can be a separate element.
- a number of commercially-available external detectors can be utilized. Many of these are fluorescent detectors because of the ease in preparing fluorescently labeled reagents. Specific examples of detectors that are available include, but are not limited to, Applied Precision ArrayWoRx (Applied Precision, Issaquah, Wash.) and the ABI 7700 (Applied Biosystems, Inc., Foster City, Calif.).
- Microfluidic devices are generally constructed utilizing single and multilayer soft lithography (MSL) techniques and/or sacrificial-layer encapsulation methods.
- MSL soft lithography
- the basic MSL approach involves casting a series of elastomeric layers on a micro-machined mold, removing the layers from the mold and then fusing the layers together.
- patterns of photoresist are deposited wherever a channel is desired.
- the foregoing fabrication methods initially involve fabricating mother molds for top layers (e.g., the elastomeric layer with the control channels) and bottom layers (e.g., the elastomeric layer with the flow channels) on silicon wafers by photolithography with photoresist (Shipley SJR 5740). Channel heights can be controlled precisely by the spin coating rate. Photoresist channels are formed by exposing the photoresist to UV light followed by development. Heat reflow process and protection treatment is typically achieved as described by Unger et al. supra. A mixed two-part-silicone elastomer (GE RTV 615) is then spun into the bottom mold and poured onto the top mold, respectively.
- GE RTV 615 A mixed two-part-silicone elastomer
- Spin coating can be utilized to control the thickness of bottom polymeric fluid layer.
- the partially cured top layer is peeled off from its mold after baking in the oven at 80° C. for 25 minutes, aligned and assembled with the bottom layer. A 1.5-hour final bake at 80° C. is used to bind these two layers irreversibly.
- this RTV device is typically treated with HCL (0.1N, 30 min at 80° C.). This treatment acts to cleave some of the Si—O—Si bonds, thereby exposing hydroxy groups that make the channels more hydrophilic.
- the device can then optionally be hermetically sealed to a support.
- the support can be manufactured of essentially any material, although the surface should be flat to ensure a good seal, as the seal formed is primarily due to adhesive forces. Examples of suitable supports include glass, plastics and the like.
- the devices formed according to the foregoing method result in the substrate (e.g., glass slide) forming one wall of the flow channel.
- the device once removed from the mother mold is sealed to a thin elastomeric membrane such that the flow channel is totally enclosed in elastomeric material.
- a thin elastomeric membrane such that the flow channel is totally enclosed in elastomeric material.
- flow channels and chambers enclosed in elastomeric material i.e., without a glass wall
- the resulting elastomeric device can then optionally be joined to a substrate support.
- the device is made as described in U.S. patent publication No. 20050072946.
- the device uses “push-up valves” described in U.S. patent publication No.
- “Push-up” refers to low actuation pressure geometry in which the membrane deflects upwards to seal off the upper fluid channel. In this geometry, the deflectable membrane is featureless and exhibits a substantially constant thickness.
- Reagents can be deposited in reaction chambers before addition of a sample to the MPD.
- a number of commercially available reagent spotters and established spotting techniques can be used to deposit the reagent(s).
- Microfluidic devices in which reagents are deposited at the reaction sites during manufacture are typically formed of three layers. The bottom layer is the layer upon which reagents are deposited. The bottom layer can be formed from various elastomeric materials as described in the references cited above on MLS methods. Typically, the material is polydimethylsiloxane (PDMS) elastomer. Based upon the arrangement and location of the reaction sites that is desired for the particular device, one can determine the locations on the bottom layer at which the appropriate reagents should be spotted.
- PDMS polydimethylsiloxane
- the deposited aqueous spot shrinks to form a very small spot.
- the deposited reagents are deposited such that a covalent bond is not formed between the reagent and the surface of the elastomer because, as described earlier, the reagents are intended to dissolve in the sample solution once it is introduced into the reaction site.
- the reagent is designed to be inactive or unavailable to a reaction until a specified condition occurs (e.g., a polymerase not activated until heated or until the addition of a necessary cofactor).
- the other two layers of the device are the layer in which the flow channels are formed and the layer in which the control and optionally guard channels are formed. These two layers are prepared according to the general methods set forth earlier in this section.
- the resulting two layer structure is then placed on top of the first layer onto which the reagents have been deposited.
- a specific example of the composition of the three layers is as follows (ration of component A to component B): first layer (sample layer) 30:1 (by weight); second layer (flow channel layer) 30:1; and third layer (control layer) 4:1. It is anticipated, however, that other compositions and ratios of the elastomeric components can be utilized as well.
- the reaction sites are aligned with the deposited reagents such that the reagents are positioned within the appropriate reaction site.
- the methods involve massive partitioning of the sample and any nucleic acid molecules it contains, and amplification (as defined herein) of target sequences in the partitioned nucleic acid molecules.
- Various versions of the methods may also involve application of particular amplication strategies, pooling of amplification products, analysis of pooled amplification products and/or other features that will be apparent upon reading this disclosure.
- This section also describes devices (i.e., massively partitioning devices, MPDs) useful in carrying out analyses according to the method.
- FIGS. 3A and 3B are flow charts illustrating partition and analysis of nucleic acids in which multiple targets are amplified in which amplicons may be pooled.
- FIG. 3B illustrates partition and analysis of nucleic acids in which, in one embodiment, target molecules in only a single chamber are amplified.
- a sample containing a plurality of nucleic acid molecules is partitioned into a plurality of sub-samples, at least two of which each comprise at least one nucleic acid molecule.
- Samples that may be analyzed according to the invention are any fluid sample that contains nucleic acids.
- a variety of types of samples can be used, so long as at least some nucleic acids can be partitioned from each other by the MPD.
- the nucleic acids can be free in solution or can be contained in particles or within cells suspended in a fluid.
- Samples may be processed so that any nucleic acids in the sample can be amplified.
- the cells or viruses can be lysed or disrupted, using such routine methods as exposure to enzymes (such as lysozyme), detergents, denaturants (such as guanidine salts) and/or physical disruption) before the sample.
- any method of liberating nucleic acids that results in nucleic acid molecules sufficiently intact and purified to amplify fragments is suitable.
- samples containing nucleic acids are cell lysates or cell fractions, water samples containing microorganisms, purified DNA resuspended in an aqueous buffer, sputum, blood, nucleated blood cells, tissue or fine needle biopsy samples, urine, peritoneal fluid, fecal samples, and fleural fluid, or cells therefrom.
- Exemplary samples include cells and cell lysates (e.g., eukaryotic cells, human cells, animal cells, plant cells, fetal cells, embryonic cells, stem cells, blood cells, lymphocytes, bacterial cells, recombinant cells and cells infected with a pathogen tissue samples), viruses, purified or partially purified DNA or RNA, environmental samples (e.g., water samples), food samples, forensic samples, plant samples and the like. It will apparent that the sample can contain other compounds and macromolecules in addition to nucleic acids. If necessary for the functioning of a microfluidic device non-nucleic acid components and/or particulates can be removed by filtration, sedimentation or other methods.
- cells and cell lysates e.g., eukaryotic cells, human cells, animal cells, plant cells, fetal cells, embryonic cells, stem cells, blood cells, lymphocytes, bacterial cells, recombinant cells and cells infected with a pathogen tissue samples
- viruses purified or partially pur
- the nucleic acids are contained in cells, organelles, or viruses and the nucleic acids are not released (e.g., the cells are not lysed) until at least after a partitioning step. Particular aspects of this embodiment are discussed in Section D, below.
- a target sequence may be predefined (i.e., known prior to analysis) or may be a sequence in a segment of a nucleic acid defined by other parameters (e.g., defined as the segment of a gene that can be amplified by a particular primer pair).
- a target sequence can be any nucleic acid sequence of interest, such as a sequence associated with a gene, a sequence that identifies a particular allele or polymorphism, a sequence that, alone in combination with other genotypic or phenotypic markers, identifies the presence in the sample of a particular organism or strain, and the like.
- a target sequence can also include sequences flanking a sequence of interest, such as the sequences flanking a SNP.
- a “target sequence” is a sequence added during an amplification step. For example, the B and U sequences discussed below in the context of a Universal Amplification method can be referred to as “target sequences” recognized by a probe or amplification primer.
- a target sequence can be found in DNA (including genomic, mitochondrial DNA, viral DNA, recombinant DNA and complementary cDNA made from RNA) or in RNA (including rRNA, mRNA and iRNA). If a target sequence is detected in a sample it is possible to deduce that the sample contains a nucleic acid molecule containing the detected sequence or its complement. For example, a sample from a human patient can be analyzed to determine whether a viral nucleotide sequence (the target sequence) is detectable in the sample, in order to diagnose (or rule out) viral infection. As another example, genomic DNA from a human patient can be analyzed to determine whether a particular polymorphism is or is not present in a subject's genome.
- fragment the nucleic acid molecules prior to the partitioning step.
- Fragmentation can be accomplished enzymatically (e.g., using restriction enzymes), mechanically or chemically.
- shearing is accomplished by passing the DNA through a channel of a MPD with a diameter (bore size) that is sufficiently small, or which varies in diameter along the length of the channel, so as to sheer large nucleic acids as they pass through.
- a sample containing a single DNA molecule e.g., a single chromosome
- Section B Methods for partitioning a sample using a MPD are provided in Section B, above.
- the terms “to partition,” “partitioning,” “partitioned,” and grammatical equivalents refer to the process of separating a sample into a plurality of sub-samples using a MPD.
- a sample is partitioned by introducing the sample into the flow channels and reaction sites with valves open and then closing the valves to isolate each sub-sample. It will be recognized that each sub-sample is contained (for at least a period of time) in a separate reaction chamber such that the sample is isolated from (not in fluidic communication with) other sub-samples. It is sometimes convenient to refer to the “sample” even after it has been partitioned into sub-samples. Thus, in some contexts “sample” can refer to the aggregate contents of the sub-samples or chambers after partition, as well as before partition.
- Effective concentration of the target occurs because, while the number of molecules of target in the sample does not change as a result of the partitioning, the number of other molecules (including molecules that can produce side reactions, e.g., primer-dimers and non-complementary DNA sequences in the sample) is linearly proportional to volume.
- the sample is partitioned into at least about 10 3 different sub-samples or reaction chambers, sometimes at least about 5 ⁇ 10 3 different sub-samples or chambers, sometimes 10 4 different sub-samples or chambers, often at least about 2 ⁇ 10 4 different sub-samples or chambers, sometimes at least about 3 ⁇ 10 4 different sub-samples or chambers, and sometimes at least about 10 5 different sub-samples or chambers.
- the sample is partitioned into between 100 and 100,000 sub-samples, more often between 1000 and 50,000 sub-samples, and sometimes between 1000 and 20,000 sub-samples.
- the volume of each sub-sample is less than about 1000 picoliters (pL), often less than about 500 pL, sometimes less than about 100 pL, and sometimes less than about 50 pL.
- the relationship between the number of nucleic acid molecules (or non-nucleic acid macromolecules, particles or cells) in a sample, the number of chambers into which the sample is partitioned, and the distribution of number of nucleic acid molecules or other entities in each chamber can be estimated using well know methods. For example, to determine the number of chambers (C) into which the number (N) particles (e.g. cells, nucleic acid molecules, etc.) would be partitioned so that most or essentially all of the chambers contained either 0 or 1 particle can be determined using a Poisson Distribution: [1]
- P(x, ⁇ ) is the probability of finding x particles if the average number of particles in a box is ⁇ . We can get this by setting the average number ( ⁇ ) such that
- ⁇ is easily determined using eqn. [1] above. For instance, if x is 0.99 (i.e. 99% chance of a chamber containing a 0 or 1 particle),
- C ⁇ 67250 chambers are required to have 99% likelihood of 0 or 1 particles per chamber.
- this calculation is provided for illustration it will be understood that any method (emperical or analytical) may be used. In some applications it will be useful to use such a calculation and adjust (e.g., dilute) the sample and/or select a MPD with an appropriate number of chambers for an increased likelihood there will be few, if any, chambers with more than a predetermined number of target molecules (e.g., 1) per chamber.
- nucleic acid “amplification” is a process that produces multiple nucleic acid molecules (called “amplicons”) based on the presence of a particular target sequence. Most often the amplicons include a base sequence that is the same as, or complementary to, the target sequence so that amplification means that the number of copies of the target sequence increases.
- amplicons are the products, for example and without limitation, of the Polymerase Chain Reaction (PCR) [see, Dieffenbach and Dvksler, 1995, PCR Primer: A Laboratory Manual.
- an amplicon is a nucleic acid with a sequence different from the target sequence and the process of amplification consists of increasing the number of amplicons if the target is present in a chamber, but not in the absence of the target sequence.
- the invention is used to simultaneously assay for multiple different target sequences in the same sample (e.g., sequences of multiple different genes or gene segments, or alternative sequences of a single gene).
- sample e.g., sequences of multiple different genes or gene segments, or alternative sequences of a single gene.
- the sample may be useful to assay the sample for the presence of several (e.g., 10, 20 or 100) different sequences each characteristic of a different pathogen.
- the different sequences are amplified in different reaction chambers.
- an assay to detect the presence of multiple mutations in different genes from an individual sample will result in analysis of products in different reaction chambers if the genes are on fragments distributed to different sub-samples.
- multiple different target sequences are assayed for and/or detected in a single reaction chamber, such as, for example, when the reaction chamber contains a single rare cell and the assay is designed to analyse several genetic loci in the cell genome.
- an assay to determine which of several possible polymorphisms e.g. defining a haplotype
- multiple primers or probes may be used to determine which of several possible target sequences are present in a single reaction chamber. Very often both types of amplification are used.
- amplification is conducted using a universal primer strategy in which each target sequence is initially amplified by a pair of target sequence specific primers that include a 3-prime domain with a gene-specific sequence and a 5-prime domain with a universal (not target specific) sequence.
- N different target sequences can be detected using primers 5′-U 1 -F N -3′ and 5′-U 2 -R N -3′ where F N and R N are forward and reverse PCR primers for each gene N, and U 1 and U 2 are sequences common to all of the primer pairs and U 1 and U 2 may be the same or different.
- Subsequent rounds of amplification can be conducted using primers 5′-U 1 -3′ and 5′-U 2 -3′. See, e.g., Zhenwu Lin et al., 1996, “Multiplex genotype determination at a large number of gene loci” Proc. Nat'l Acad. Sci USA 93: 2582-87. When used in an MPD this strategy allows use of a low concentration of target specific primers (thereby reducing expense and the chances of primer dimer and other unintended side reactions) and a higher concentration of universal primers.
- the multiplex amplification is carried out in a MPD using the primers and strategy described below in Section C(v).
- Amplification reagents can be provided by prepositioning reagents in reaction chambers, by combining reagents with the sample before partitioning, by a combination of prepositioning and combining, or by any other suitable method.
- Specific amplification reagents will depend on the amplification method and sample, but can include primers, polymerase, reverse transcriptase, nucleotides, cofactors, metal ions, buffers, and the like. Methods for prepositioning reagents in a microfluidic device have been described (see McBride et al., supra).
- detection reagents such as labeled probes can be provided by prepositioning and/or combining.
- thermocycling necessary for a PCR-type amplification reaction can be accomplished by placing the device on a thermocycling plate and cycling the device between the various required temperatures for melting of the DNA duplex (either target or amplicon), annealing of primers, and DNA synthesis.
- a protocol with an initial ramp to 95° C. and maintain for 1 m; three step thermocycling for 40 cycles [92° C. for 30 s, 54° C. for 30 s, and 72° C. for 1 m] or two step thermocycling for 40 cycles [92° C. for 30 s and 60° C. for 60 s] can be used.
- thermocycling plates are available from commercial sources, including for example the ThermoHybaid Px2 (Franklin, Mass.), MJ Research PTC-200 (South San Francisco, Calif.), Eppendorf Part#E5331 (Westbury, N.Y.), Techne Part#205330 (Princeton, N.J.).
- a single target sequence in the sample is amplified, more often at least 2, at least 3, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, or at least 100 different target sequences are amplified.
- sufficient reagents are provided to amplify more than one target sequence.
- the amplification procedure can produce from zero (if no target sequence is present) to 100 or more different amplicons.
- Any particular chamber may have zero, one or more than one amplicons species (where amplicons corresponding to the same target sequence are of the same “species”) depending on the nature of the assay and sample.
- At least about 10 3 , at least about 10 4 , at least about 10 5 , at least about 10 6 , at least about 10 7 , or at least about 10 8 amplicon molecules are produced corresponding to some or all of the target sequences present in the sample. Most typically, from about 10 7 to about 10 9 amplicon molecules are produced for each target sequence, although the number may be lower when multiple reactions are conducted in a single reaction chamber.
- the amplicon products can be detected in individual chambers and/or they can be pooled for subsequent detection and analysis (as described below in Section C(vi)). That is, amplicons can be detected and then pooled, pooled without previously being detected, or detected and not subsequently pooled.
- Amplicons can be detected and distinguished (whether isolated in a reaction chamber or at any subsequent time) using routine methods for detecting nucleic acids.
- Amplicons comprising double-stranded DNA can be detected using intercalation dyes such as SYBRTM, Pico Green (Molecular Probes, Inc., Eugene, Oreg.), ethidium bromide and the like (see Zhu et al., 1994, Anal. Chem. 66:1941-48) and/or gel electrophoresis. More often, sequence-specific detection methods are used (i.e., amplicons are detected based on their nucleotide sequence).
- FRET-based detection is a preferred method for detection.
- FRET-based assays a change in fluorescence from a donor (reporter) and/or acceptor (quencher) fluorophore in a donor/acceptor fluorophore pair is detected.
- the donor and acceptor fluorophore pair are selected such that the emission spectrum of the donor overlaps the excitation spectrum of the acceptor.
- FRET and template extension reactions utilize a primer labeled with one member of a donor/acceptor pair and a nucleotide labeled with the other member of the donor/acceptor pair.
- the donor and acceptor Prior to incorporation of the labeled nucleotide into the primer during an template-dependent extension reaction, the donor and acceptor are spaced far enough apart that energy transfer cannot occur. However, if the labeled nucleotide is incorporated into the primer and the spacing is sufficiently close, then energy transfer occurs and can be detected.
- Quantitative Real Time PCR A variety of so-called “real time amplification” methods or “real time quantitative PCR” methods can also be used to determine the quantity of a target nucleic acid present in a sample by measuring the amount of amplification product formed during or after the amplification process itself. Fluorogenic nuclease assays are one specific example of a real time quantitation method which can be used successfully with the devices described herein. This method of monitoring the formation of amplification product involves the continuous measurement of PCR product accumulation using a dual-labeled fluorogenic oligonucleotide probe—an approach frequently referred to in the literature as the “TaqMan” method. See U.S. Pat. No. 5,723,591
- Molecular Beacons With molecular beacons, a change in conformation of the probe as it hybridizes to a complementary region of the amplified product results in the formation of a detectable signal.
- the probe itself includes two sections: one section at the 5′ end and the other section at the 3′ end. These sections flank the section of the probe that anneals to the probe binding site and are complementary to one another.
- One end section is typically attached to a reporter dye and the other end section is usually attached to a quencher dye.
- the two end sections can hybridize with each other to form a hairpin loop.
- the reporter and quencher dye are in sufficiently close proximity that fluorescence from the reporter dye is effectively quenched by the quencher dye.
- Hybridized probe in contrast, results in a linearized conformation in which the extent of quenching is decreased.
- Probes of this type and methods of their use are described further, for example, by Piatek et al., 1998, Nat. Biotechnol. 16:359-63; Tyagi, and Kramer, 1996, Nat. Biotechnology 14:303-308; and Tyagi, et al., 1998, Nat. Biotechnol. 16:49-53 (1998).
- Scorpion The Scorpion detection method is described, for example, by Thelwell et al. 2000, Nucleic Acids Research, 28:3752-3761 and Solinas et al., 2001, “Duplex Scorpion primers in SNP analysis and FRET applications” Nucleic Acids Research 29:20.
- Scorpion primers are fluorogenic PCR primers with a probe element attached at the 5′-end via a PCR stopper. They are used in real-time amplicon-specific detection of PCR products in homogeneous solution. Two different formats are possible, the ‘stem-loop’ format and the ‘duplex’ format. In both cases the probing mechanism is intramolecular.
- the basic elements of Scorpions in all formats are: (i) a PCR primer; (ii) a PCR stopper to prevent PCR read-through of the probe element; (iii) a specific probe sequence; and (iv) a fluorescence detection system containing at least one fluorophore and quencher.
- the resultant amplicon contains a sequence that is complementary to the probe, which is rendered single-stranded during the denaturation stage of each PCR cycle. On cooling, the probe is free to bind to this complementary sequence, producing an increase in fluorescence, as the quencher is no longer in the vicinity of the fluorophore.
- the PCR stopper prevents undesirable read-through of the probe by Taq DNA polymerase.
- Invader assays are used particularly for SNP genotyping and utilize an oligonucleotide, designated the signal probe, that is complementary to the target nucleic acid (DNA or RNA) or polymorphism site.
- a second oligonucleotide, designated the Invader Oligo contains the same 5′ nucleotide sequence, but the 3′ nucleotide sequence contains a nucleotide polymorphism.
- the Invader Oligo interferes with the binding of the signal probe to the target nucleic acid such that the 5′ end of the signal probe forms a “flap” at the nucleotide containing the polymorphism.
- Cleavase enzyme cleaves the 5′ flap of the nucleotides. The released flap binds with a third probe bearing FRET labels, thereby forming another duplex structure recognized by the Cleavase enzyme. This time the Cleavase enzyme cleaves a fluorophore away from a quencher and produces a fluorescent signal.
- the signal probe will be designed to hybridize with either the reference (wild type) allele or the variant (mutant) allele. Unlike PCR, there is a linear amplification of signal with no amplification of the nucleic acid.
- Padlock probes are long (e.g., about 100 bases) linear oligonucleotides. The sequences at the 3′ and 5′ ends of the probe are complementary to adjacent sequences in the target nucleic acid. In the central, noncomplementary region of the PLP there is a “tag” sequence that can be used to identify the specific PLP. The tag sequence is flanked by universal priming sites, which allow PCR amplification of the tag. Upon hybridization to the target, the two ends of the PLP oligonucleotide are brought into close proximity and can be joined by enzymatic ligation. The resulting product is a circular probe molecule catenated to the target DNA strand.
- any unligated probes i.e., probes that did not hybridize to a target
- an exonuclease which may be introduced before or after a pooling step.
- Hybridization and ligation of a PLP requires that both end segments recognize the target sequence. In this manner, PLPs provide extremely specific target recognition.
- the tag regions of circularized PLPs can be amplified and resulting amplicons detected.
- TaqMan real time PCR can be carried out to detect and quantitate the amplicon.
- the presence and amount of amplicon can be correlated with the presence and quantity of target sequence in the sample.
- PLPs see, e.g., Landegren et al., 2003, Padlock and proximity probes for in situ and array-based analyses: tools for the post-genomic era, Comparative and Functional Genomics 4:525-30; Nilsson et al., 2006, Analyzing genes using closing and replicating circles Trends Biotechnol. 24:83-8; Nilsson et al., 1994, Padlock probes: circularizing oligonucleotides for localized DNA detection, Science 265:2085-8.
- multiplex amplification systems can be used in conjunction with the present invention.
- several different targets can be detected simultaneously by using multiple differently labeled probes each of which is designed to hybridize only to a particular target. Since each probe has a different label, binding to each target to be detected based on the fluorescence signals.
- analyses can be conducted in which the different labels are excited and/or detected at different wavelengths in a single reaction.
- UA primers can be used to determine whether or not any one or more of a number of different target nucleic acid sequences are present in a sample (without necessarily identifying which of the several target sequences is present). If the assay indicates that at least one of the different nucleic acid sequences is present in the sample, subsequent analysis can be conducted to determine which of the different sequences is present.
- two-step analysis is advantageous in many applications. For example, using the present invention, in a first step a sample can be assayed to determine whether any of 100 (for example) different pathogenic agents is present in the sample. If it is determined in the first step that at least one pathogenic agent is present, the sample can be subjected to further analysis to identify and characterize the particular pathogen.
- the invention provides a method for detecting multiple amplification products (i.e., amplicons) using the Universal Amplification method.
- the total number of target sequences detected is usually at least two, and is sometimes at least 5, more often at least 10, at least 20 or at least 30.
- the total number of target sequences is between 2 and 100, between 5 and 100, between 10 and 100, between 20 and 100, or between 30 and 100.
- the total number of target sequences is between 2 and 50, between 5 and 50, between 10 and 50, between 20 and 50, or between 30 and 50.
- the total number of target sequences is more than 100.
- the UA method makers use of three or more types of primers:
- the Type 1 primer has the structure 5′-U F -B X -F N -3′ where U F is a universal forward primer sequence, B X is a sequence recognized by a detectable (e.g., detectably labeled) labeled probe, Probe X, and F is a forward primer sequence specific to a target sequence N so that F 1 is primer for a first target sequence, F 2 is a primer sequence for a second target sequence, and so on.
- Probe X can be a molecular beacon, Taqman-type probe, or other probe (such as, but not limited to, those described above) that specifically binds or hybridizes to sequence B X .
- the Type 2 primer has the structure 5′-U R -R N -3′ where U R is a universal reverse primer sequence and R N is a primer specific to a target sequence N so that R 1 is primer for a first target sequence, R 2 is a primer for a second target sequence and so on.
- U R may or may not be the same sequence as U F .
- 5′-U R -3′ has the same sequence as 5′-U F -3′.
- the Type 3 primer comprises the sequence 5′-U F -3′ (or 5′-U 1 -3′).
- the Type 4 primer comprises the sequence 5′-U R -3′ (or 5′-U 2 -3′).
- Each pair of Type 1 and Type 2 primers is specific to a particular target.
- the cognate pair of primers that amplify the same target is a “UA primer pair.”
- twenty different primer pairs can be prepared, i.e., 5′-U 1 -B X -F [1 ⁇ 2] -3′ and 5′-U 2 ′-R [1 ⁇ 20] -3′.
- the various pairs of Type 1 and Type 2 primers are combined at low concentrations with the sample, and Type 3 and Type 4 primers are added at a higher concentration.
- the Type 1 and Type 2 primers will amplify any target sequences present in a sample or sub-sample. It will be appreciated that U 1 and U 2 sequences can be designed with sequences not present (or unlikely to be present) in the initial sample nucleic acid, to avoid amplification of non-target sequences in the sample. For example, for analysis of human DNA, U 1 and U 2 can be selected to have sequences not found on the human genome.
- the amplification products generated in the first rounds of amplification are themselves amplified by the Type 3 and Type 4 primers. The resulting double stranded amplification products will have the structure (showing one strand):
- Primer concentration(s) will vary with the length, composition, and nature of the sample and targets. Those primer pairs with sequences specific to each of the targets (e.g., Type 1 and 2 primers) are required only in the first few rounds of amplification and can be provided in very small quantities (for example and not limitation, e.g., typically less than about 50 nM, more often less than about 30 nM and sometimes less than about 20 nM). Type 3 and 4 primers can be provided at somewhat higher concentration (for example and not limitation, e.g., typically from about 100 nM to 1 uM, such as from about 200 nM to about 900 nM). The practicioner guided by this disclosure will be able to select appropriate concentration using routine methods.
- the method can be modified in a variety of ways to achieve particular results.
- a relatively small number of probe sequences can be used with a larger number of unique target sequences, with different classes of target specific sequences associated with differently labeled probes. For example, if target sequences 1-20 are characteristic of a viral pathogen, target sequences 21-40 are characteristic of a bacterial pathogen, and target sequences 41-45 are positive control sequences (human genes), amplification of a human patient sample could give zero, one or more than one of the following 45 amplification products:
- probes B V hybridizes to Set 1 products
- B B hybridizes to Set 2 products
- B C hybridizes to Set 3 products
- the classes of amplification products can be detected and distinguished.
- the human sample produced any amplicon to which Probe B V hybridized and emitted signal it would indicate that the patient was infected with one of 20 viruses.
- the precise identity of the viral pathogen could be determined in a second assay step.
- the human sample produced any amplicon to which Probe B B hybridized and emitted signal (different from the signal emitted by Probe B V ) it would indicate that the patient was infected with one of 20 bacteria.
- sample such as food or agricultural sample can be screened for many different pathogens simultaneously and if any hits are detected the sample can be selected for further analysis to determine which of the many pathogen(s) was responsible for the signal. If there is no signal, the sample can be concluded to be pathogen free.
- the contents of the sub-samples, including any amplicons in them are pooled (i.e., allowed to combine or mix at least partially). Pooling combines the amplicons (if present) from multiple sub-samples.
- Pooling can be accomplished by, for example, opening the valves of an elastomeric microfluidic device in which partitioning and amplification occurred such that the contents of multiple sub-samples (e.g., at least about 10 3 , at least about 5 ⁇ 10 3 , at least about 10 4 , at least about 2 ⁇ 10 4 , at least about 3 ⁇ 10 4 , or at least about 10 5 sub-samples) are in fluidic communication with each other, constituting a “post-amplification sample” that consists of the contents of all of the chambers.
- Amplicons can mix by diffusion, which can be accelerated using thermal, mechanical, acoustic, or chemical energy.
- pooling occurs primarily as a result of active mixing (e.g., by pumping the fluid through flow channels in the device using a rotary peristaltic pump or other mechanism).
- active mixing e.g., by pumping the fluid through flow channels in the device using a rotary peristaltic pump or other mechanism.
- a portion, all or substantially all of the post-amplification sample can be pumped out of or otherwise withdrawn from the device, thereby pooling and mixing any amplicons present in the sample. Any method that results in a distribution of amplicons sufficient to carry out subsequent detection steps may be used.
- the sub-samples are pooled (by releasing valves) and one-fifth of the volume of the post-amplification sample removed from the device or from the partition region of the device (see Section C(viii), below). If the amplicons had diffused to equilibrium in the post-amplification sample, and assuming no loss of material, the one-fifth volume would contain about 20,000 molecules of each of the three amplicons. If diffusion was less than complete, the one-fifth volume could contain unequal amounts of each amplicon, for example 50,000 molecules of amplicon A, 20,000 molecules of amplicon B and 15,000 molecules of amplicon C.
- all or substantially all, of the post-amplification sample can be withdrawn from the device, thereby mixing any amplicons present in the sample.
- the amplicon pool can be used for subsequent analyses.
- the amplicon pool is divided into a plurality of aliquots and each aliquot separately analyzed to determine a property (e.g., a nucleotide sequence or the presence or absence of a predetermined nucleotide sequence) of an amplicon or amplicons in that aliquot.
- the volume of the amplicon pool can be increased by addition of a suitable solution such as aqueous buffer or a reaction mixture containing amplification and/or detection reagents.
- the amplicon pool can be divided into aliquots manually or can be divided using an appropriately designed MPD (see Section C(viii), below).
- each of the aliquots from the amplicon pool will contain essentially the same set of amplicons (i.e., the same amplicon species will be represented in each aliquot).
- Each of the aliquots can be used for a different analysis.
- a first aliquot can be assayed for the presence of a first target sequence (e.g., a first SNP in an amplified gene sequence), a second aliquot can be assayed for the presence of a second target sequence (e.g., a second SNP in the same amplified gene sequence), a third aliquot can be assayed for the presence of a third target sequence (e.g., a first SNP of a different amplified gene) and so on.
- a first target sequence e.g., a first SNP in an amplified gene sequence
- a second target sequence e.g., a second SNP in the same amplified gene sequence
- a third aliquot can be assayed for the presence of a third target sequence (e.g., a first SNP of a different amplified gene) and so on.
- target sequences of interest are not limited to SNPs.
- amplicons can be carried out using any desired technique including, without limitation, hybridization to a target nucleic acid or array of targets, PCR amplification, FRET-assays, hybridization to probes, and the like.
- massive partitioning is accomplished using an elastomeric MPD.
- Subsequent analyses can also be accomplished using any suitable assay.
- an elastomeric microfluidic device is used for subsequent analyses.
- the initial partitioning and amplification, the subsequent mixing of applications, and the subsequent analysis of amplicons are carried out using different sections (i.e., different banks) of the same the same device.
- an elastomeric device can be fabricated with three regions: a first region that is a MPD in which target sequences, cells or molecules are amplified in individual chambers to produce amplicons and then allowed to mix to produce an amplicon pool, a second region (which can be as small as a single flow channel) by which the amplicon pool is transferred to the third region, and a third region having a plurality of flow channels with a region of each flow channel defining a reaction site in which subsequent analysis of the amplicon pool occurs.
- the flow channels in the third region are blind flow channels with reaction sites near the channel terminus.
- a schematic of an exemplary device is shown in FIG. 2 . In this schematic five control channels (1, 2, 3, 4 and 5) are shown in black.
- a branched flow channel system is shown in gray. It will be appreciated, as discussed above, that the flow channel configuration need not be branched.
- a sample containing an amplification mixture and nucleic acids is injected into inlet A with the values formed by control channels 1 and 2 open, and control channel 3 actuated (closed).
- Control channel 2 is then actuated to isolate the sample in multiple chambers (B).
- the samples are then subject to thermocycling and optionally detection of the amplification products (e.g., using a commercially available fluorescence reader).
- Control channel 1 is then closed and control channel 2 opened to allow mixing of amplicons in the various chambers to produce an amplicon pool, a portion of which is then pumped into blind channels (D) with control channels 3, 4 (if present) and 5 open.
- control channels 2 and 3 are both opened and a portion of the amplicon pool is pumped to a mixing chamber (C) with control channel 4 closed.
- Control channel 3 is then closed and channels 4 and 5 are opened and portion of the amplicon pool is pumped into blind channels (D).
- Control channel 5 is then closed isolating blind reaction chambers (E) and the subsequent round of analysis takes place.
- the device is configured so that reagents can be added to the pooled amplicon sample; for example, the mixing chamber (C) shown in FIG. 2 may be fluidically linked to a reservoir containing reagents (e.g., nuclease, probes or primers) that can be added prior to distributing the amplicon pool into a reaction chambers.
- reagents e.g., nuclease, probes or primers
- the invention provides a system for analysis of nucleic acids, proteins or cells comprising a massively partioning device and an external collection reservoir for collection of an amplicon pool.
- the external reservoir can be any type of container or tube that is fluidically connected to the MPD, so that the contents of the MPD chambers can be transferred from the MPD to the reservioir. Transfer can be by displacement of the MPD contents using a displacement fluid, by active pumping, or by other means.
- the invention provides a system for analysis of nucleic acids, proteins or cells comprising a massively partitioning device, optionally including an integral or external reservoir for collection of an amplicon pool, and an (additional) external component.
- the MPD includes a region with a plurality of flow channels defining a reaction sites for subsequent analysis of the amplicon pool aliquots (e.g., the “third” region of the device described above in Section (viii).
- the invention provides a system for analysis of nucleic acids, proteins or cells comprising a massively partitioning device as described in Section (viii) above, where the MPD has three regions: a first region that is a MPD in which target sequences, cells or molecules are amplified in individual chambers to produce amplicons and then allowed to mix to produce an amplicon pool, a second region (which can be as small as a single flow channel) by which the amplicon pool is transferred to the third region, and a third region having a plurality of flow channels with a region of each flow channel defining a reaction site in which subsequent analysis of the amplicon pool occurs.
- a massively partitioning device as described in Section (viii) above, where the MPD has three regions: a first region that is a MPD in which target sequences, cells or molecules are amplified in individual chambers to produce amplicons and then allowed to mix to produce an amplicon pool, a second region (which can be as small as a single flow channel) by which the amplicon
- Additional external components of the system may include sensors, actuators (e.g., pumps; see U.S. Pat. No. 6,408,878), control systems for actuating valves, data storage systems, reagent storage units (reservoirs), monitoring devices and signal detectors
- Signal detectors may detect visible, fluorescent, and UV light (intensity, scattering, absorption) luminescence, differential reflectivity, electrical resistance, resistivity, impedance, or voltage, in chambers or reaction sites.
- the external component is a temperature control component such as a thermocycler (e.g., Peltier device, resitive heaters, and heat exchangers; see e.g., U.S. Pat. No. 6,960,437 B2).
- the invention provides a system for analysis of nucleic acids, proteins or cells comprising a massively partitioning device, optionally including an integral or external reservoir for collection of an amplicon pool, optionally including a plurality of flow channels defining a reaction sites for subsequent analysis of the amplicon pool aliquots, and optionally including and an additional reagent positioned in the chambers of the MPD and/or the reaction sites for subsequent analysis of the amplicon pool aliquots.
- additional reagents include enzymes (e.g., nuclease, polymerase, or ligase); primers and probes (PCR primers. molecular beacons, padlock probes, proximity ligation probes, Universal Amplification primers), amplification reagents and the like.
- particular systems may comprise an MPD and a heat source (e.g., thermocycler) positioned to regulate the temperature of the contents of reaction chambers.
- heat is transmitted from the heat source to the MPD by conduction (e.g., the heat source being adjacent and in contact with the MPD).
- the MPD is fixed (e.g., clamped) to the heat source.
- particular systems may comprise an MPD and a signal detector positioned to detect signal emanating from reaction chambers in the MPD system.
- a fluorescent signal is detected.
- the system includes an appropriately programmed computer coupled to the signal detector capable of storing information such as the position, intensity and/or duration of a signal emanating from reaction chambers in the MPD system.
- the MPD comprises reaction chambers for analysis of amplicon pool aliquots
- the signal detector, heat source, or other component of the system may be associated with those reaction chambers, reaction chambers produced in the partitioning step, or both.
- Other particular systems may comprise a MPD comprising prepositioned reagents in one or more reaction chambers or mixing chambers.
- a sample containing genomic DNA from the subject is obtained.
- a small number of genome equivalents is sufficient for analysis.
- the sample may be from a small number of cells (for example, fewer than 10 cells, and as few as one cell) which may be treated to release and fragment genomic DNA.
- isolated or purified DNA may be used.
- the DNA is fragmented by shearing, enzymatic or chemical cleavage, or other methods known in the art.
- the DNA is sheared by transport through a channel with varying cross-dimensions.
- the reagents for amplification of target sequences are added to the sample.
- the amplification reagents include the following:
- Primer pairs for each of the 200 gene segments to be analyzed can be selected, for example, to (i) amplify a target polymorphic site sequence only if site has a particular sequence (i.e., a specified SNP allele is present) or (ii) amplify the target polymorphic site sequence using primers that flank the SNP site, so that the segment is amplified without regard to what SNP is present.
- Each primer pair includes both a target specific sequence and one of two 5′ universal sequences shared by all of the forward or all of the reverse primers, allowing all of the amplicons produced using the target specific primers to be amplified with the same universal primers.
- Primers are selected so that all of the first round amplifications (using target specific primers) can occur under the same reaction conditions.
- Amplification reagents (polymerase, cofactors, nucleotides, metal ions, buffer, etc.).
- the reagents may be added to the sample before partition, may be pre-positioned in the reaction chambers, or some reagents may be added and others pre-positioned.
- the sample is injected into the partitioning channel system of a MPD having 40,000 chambers. After injection of the sample, valves are closed creating 40,000 isolated reaction chambers. Each reaction chamber contains all of the probes described above, and some of the chambers contain a nucleic acid molecule with a target sequence of interest as a consequence of the partitioning.
- the MPD is placed on a thermocycler and cycled using an appropriate protocol (e.g., 2 min at 51° C., 1 sec at 96° C. and 59 sec at 95° C., followed by 40 cycles of 1 min at 58° C., 1 sec at 96° C. and 59 sec at 95° C.). Following amplification, the values are opened and sub-samples allowed to mix (e.g., by diffusion or active mixing) producing the amplicon pool.
- a portion of the resulting amplicon pool is withdrawn from the MPD and distributed into two hundred (200) aliquots, and each aliquot is subjected to a different SNP assay.
- different sets of SNP assays can be conducted using multiplex methods.
- the individual SNP assays can be carried out using, for example, a TaqmanTM-type probe, Molecular Beacon, Scorpion, or other detection methods and detected using a fluorescence detector.
- a nucleic acid analysis is conducted on a single cell.
- Such an analysis is useful for diagnostic or prognostic methods when tissue is limited such as, for example, genetic testing of a single blastocyst of a pre-implantation embryo produced using in vitro fertilization techniques.
- Such testing is also useful in the study or cloning of non-human animals.
- blastocyst cells obtained from a non-human animal can be assayed for the presence, expression or characteristics of a transgene or endogenous gene. It can be verified that the genotype or expression profile of the embryo is consistent with the goals of the researcher prior to implantation into a surrogate mother, resulting in savings of time and resources.
- Such testing is also useful in forensic analysis in which very few cells may be available or in which cells must be analyzed individually because a sample is contaminated with cells from multiple sources.
- FIG. 3C Analysis of nucleic acids of a single cell is illustrated by the flow chart in FIG. 3C . It will be appreciated that the figure is provided to assist the reader in understanding the invention, and is not intended to limit the invention in any fashion.
- the single cell (or small number of cells) is provided in a solution or combined with a solution.
- the cell is treated to release DNA. Any number of methods for cell lysis (e.g., using sonication, denaturants, etc.) are suitable.
- genomic DNA is being analyzed it is fragmented. The desired fragment size will be based on the method of detection of the target sequence and the number of reaction chambers on the chip. The goal is to end up with large enough fragments so that target sequences can be amplified (typically >300 bp) and enough fragments so that different amplicons (i.e., amplicons corresponding to different sequences) will be generated is separate reaction chambers.
- the intended average size will depend on the number of target sequences to be detected and the number of partitions available.
- Fragments can be created by restriction digestion or other DNA fragmentation methods.
- DNA is sheared by driving it thorough a narrow opening.
- a MPD can be designed with a via or flow channel of sufficiently small diameter narrowness to shear DNA to the desired fragment size.
- the diameter of the via or flow channel varies across its length (e.g., narrow-wide-narrow-wide) to drive the fragmentation.
- the sample is introduced into a WD and the MPD valves are actuated to partition the DNA fragments, or RNA molecules, into separate reaction chambers.
- Reagents sufficient to amplify each of the target sequences of interest are provided in each reaction chamber.
- 50 different loci containing SNPs are of interest, and at each of the 50 polymorphic loci there are two different possible sequences at the SNP site, with the 100 total different target sequences designated SNP 1A, 1B, 2A, 2B, . . . 50A, and 50B.
- the reagents can be added to the solution containing the intact cell, can be prelocated in the reaction chambers, or some combination of the two.
- the amplification reagents include primers sufficient to amplify gene segments spanning each of the 50 loci to produce the SNP site and 40 basepairs of flanking sequence on each side.
- UA amplification primers may be used.
- Amplification is then carried out (e.g., by thermocycling if the amplification method is PCR or reverse transcription-P CR). Amplicons are produced in those reaction chambers that contain a nucleic acid molecule (i.e., DNA fragment or RNA molecule) comprising one of the target sequences.
- valves are opened and amplicons allowed to mix to produce an amplicon pool.
- the pool is than divided into 100 different aliquots (optionally using a duel bank MPD as described in Section C(viii), above).
- a single assay is carried out for an individual SNP using, for example, a TaqmanTM-type probe, Molecular Beacon, Scorpion, or other detection methods known in the art.
- a sample is assayed for the presence of 150 different pathogens.
- exemplary samples for the method include (i) a sample is obtained from a patient, (ii) an environmental sample (e.g., from a pond or reservoir) and (iii) a sample from a poultry processing facility.
- the reagents for amplification of target sequences are added to the sample.
- the amplification reagents include the following:
- UA primer pairs for gene segments found in fifty different bacterial pathogens.
- the forward primer of these UA primer pairs includes a recognition site for a molecular beacon labeled with the blue fluorescing dye Cy 5.5.
- UA primer pairs for gene segments found in fifty different fungal pathogens.
- the forward primer of these UA primer pairs includes a recognition site for a molecular beacon labeled with the green fluorescing dye 6-FAM (Fluorescein).
- UA primer pairs for gene segments found in fifty different viral pathogens.
- the forward primer of these UA primer pairs includes a recognition site for a molecular beacon labeled with the red fluorescing dye Cy 3.
- Type 3 and Type 4 primers corresponding to the UA primer pairs Primers 5′-U A -3′ and 5′-U B -3′.
- Prinmer sequences are selected so that all of the UA primer pairs produce amplicons that can be amplified using the same Type 3 and Type 4 primers; and all of the first round amplifications can occur under the same reaction conditions.
- Amplification reagents (polymerase, cofactors, nucleotides, metal ions, buffer, etc.).
- the reagents may be added to the sample before partition, may be prepositioned in the reaction chambers, or some reagents may be added and others prepositioned.
- the sample is injected into the partitioning channel system of a MPD having 40,000 chambers. After injection of the sample each valves are closed creating 40,000 isolated reaction chambers. Each reaction chamber contains all of the probes described above, and some of the chambers contain a nucleic acid molecule with a target sequence of interest.
- the MPD is placed on a thermocycler and cycled using an appropriate protocol (e.g., 2 min at 51° C., 1 sec at 96° C. and 59 sec at 95° C., followed by 40 cycles of 1 min at 58° C., 1 sec at 96° C. and 59 sec at 95° C.). Following amplification, the device is imaged using a commercially available, modified, or custom made fluorescence reader.
- chambers fluorescening blue indicates that there is at least one bacterial pathogen present in the sample.
- the appearance of chambers fluorescening green indicates that there is at least one fungal pathogen present in the sample.
- the appearance of chambers fluorescesing red indicates that there is at least one viral pathogen present in the sample.
- the values of the MPD are opened and sub-samples allowed to pool by diffusion or active mixing, producing the amplicon pool. A portion of the resulting amplicon pool is withdrawn from the MPD and divided into fifty (50) aliquots each containing reagents for identification of one of the 50 viruses assayed for in the initial part of the screen.
- An exemplary detection method uses 50 molecular beacons (one in each aliquot) that each recognize a different virus specific sequence in the amplicon. By determining which of the molecular beacons bind a target sequence present in the amplicon pool (or the portion contained in an aliquot) the identity of the pathogen is determined.
- Proteins and other biomolecules can be partitioned in a manner analogous to that described above for nucleic acid molecules. Any suitable method can be used to produce an amplification product indicative of the presence of a protein. In one method, a proximity ligation procedure is used. The proximity ligation procedure is analogous in certain respects to the use of padlock probes, described above in Section C, but is used for detecting proteins and other analytes. The proximity ligation procedure uses specific protein binding agents linked to oligonucleotides. Examples of specific protein binding agents include, but are not limited to, antibodies (defined as any specific binding agent comprising a CDR, including phage display antibodies, single chain antibodies, monoclonal antibodies, and the like) and nucleic acid aptamers.
- a pair of protein binding agents that recognize different epitopes of a target protein are used.
- Each of the binding agents is attached (e.g., via streptavidin-biotin linkage) to a synthetic DNA strand that includes a PCR primer binding site.
- the synthetic DNA strands are brought into proximity when both binding agents bind the same target molecule.
- a connector oligonucleotide that hybridizes to sequences at the ends of both of the synthetic DNAs is added in excess, bringing termini of the DNA strands together so that they can be joined by ligase.
- a region of the ligated sequence may be amplified and detected by real time PCR.
- unligated strands are not amplified and therefore not detected in the assay.
- the assay also may be used to assay for non-protein molecules that are specifically bound by a nucleic acid aptamer, antibody or other binding agent.
- Proximity ligation methods can also be used to detect nucleic acid targets. In this approach, nucleotide sequences complementary to the target are used rather than protein binding agents.
- individual cells are isolated by partitioning using a MPD, and one or more properties of one or more of the individual cells are determined. Using this method, analysis of individual cells can be carried out without background from other cells in a sample.
- cell properties include
- nucleic acid is RNA or DNA; recombinant or naturally occurring; cellular or viral; nuclear, cytoplasmic or from an organelle;
- combinations of two, three, or more than three different properties e.g., the presence in a cell of two different target nucleic acid sequences; the presence in a cell of a target nucleic acid sequence and a protein epitope; a change in a metabolic property of a cell and expression of a nucleic acid sequence in the cell; a cell surface epitope and secretion of a cytokine by the cell in response to a stimulus, etc.).
- a liquid sample containing a plurality of separable cells is introduced into the MPD and the cells partitioned.
- a “separable cell” is a cell that is physically separated from other cells and can be partitioned into a chamber without other cells.
- seperable cells can be obtained from a patient or other source with little processing.
- liver biopsy, cultured cells, blastocyte it will be necessary to disrupt a tissue or aggregate mechanically, enzymatically, or using other methods well known in the art.
- cells that can be assayed in this method include eukaryotic cells, human cells, animal cells, plant cells, fetal cells, embryonic cells, stem cells, blood cells, lymphocytes, bacterial cells, recombinant cells and cells infected with a pathogen.
- eukaryotic cells human cells, animal cells, plant cells, fetal cells, embryonic cells, stem cells, blood cells, lymphocytes, bacterial cells, recombinant cells and cells infected with a pathogen.
- the method includes partitioning a sample comprising a plurality of seperable cells into at least 10 3 separate reaction chambers in an MPD, where after partitioning at least two chambers comprise exactly one cell each.
- the sample is partitioned into at least 10 4 separate reaction chambers, at least 2 ⁇ 10 4 separate reaction chambers or at least 3 ⁇ 10 4 separate reaction chambers.
- the number of cells introduced into the MPD and/or the number of chambers in the MPD are selected so that most or virtually all of the chambers contain either no cells or a single cell. This can be determined from the Poisson distribution (based on the number of chambers in the device and number of cells injected into the device) or empirically (e.g., by detecting the number of chambers that contain cells).
- at least 90% of the chambers contain zero or one cell, often at least 99% of the chambers contain zero or one cell, and in some cases virtually all of the chambers contain zero or one cell.
- Each of the plurality of chambers contains the same reagents for conducting the analysis. All or some of these reagents can added to the sample or cells prior to injection into the device and/or can be prepositioned in the chambers and/or provided in inactive form, as described above. Because the reagents are constant, any chamber-to-chamber differences in analytical results are due to the presence of different cells (or no cell) and reflect differences in the properties of the cells. By detecting different signals from different chambers, a property or properties of cells in chambers can be determined and compared. This method finds a variety of applications in which it is informative to determine that a sample contains a cell having two or more properties detectable in separate assays. This method also finds a variety of applications in which the cell of interest is a rare cell in a background of many other cells.
- reagents used will depend on the type of assay contemplated and specific properties to be detected. Generally the properties that can be assayed can be divided into two groups: properties determined based on the presence or absence of a nucleic acid target sequence and properties determined based on something other than the presence or absence of a nucleic acid target sequence. In many applications both a nucleic acid analysis and detection of a different type of property are carried out.
- reagents suitable for nucleic acid analysis include those used for nucleic acid amplification (including but not limited to the PCR, SPIA, Invader, and other amplification methods described in this disclosure or known in the art) and those used for detection (including but not limited to, FRET based methods and other detection methods described in this disclosure or known in the art).
- the UA amplification/detection methods described in Section C(v) are used.
- proximity ligation and FRET-based assays can be used to detect the presence of proteins or epitopes in a cell; presence, activation or change in enzymatic activities; intracellular organelle function; pathogen (e.g., viral) infection; intracellular signaling; protein-protein interactions; protein-DNA interactions; colocalization of proteins cell cycle; metabolic reactions such as generation of reactive oxygen species; mitochondrial membrane potential; apotosis; intracellular organelle function; changes in representations of cell types in cell populations; and subcellular localization of macromolecules.
- pathogen e.g., viral
- the cell(s) is destroyed in the course of the process of detecting the cell property.
- numerous fluorescence based assays that can be carried out on living cells can readily be adapted for use in the present invention and/or reagents used in such assays may be used in the methods of the present invention. See, e.g., Dirks et al., 2003, Visualizing RNA molecules inside the nucleus of living cells, Methods, 29:51-7; Santangelo et al., 2004, Dual FRET molecular beacons for mRNA detection in living cells, Nucleic Acids Res.
- Pathol., 16:778-785 Wang et al., 2003, Genomic instability and endoreduplication triggered by RAD 17 deletion, Genes & Dev., 17:965-970; Williams et al., 2003, Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts, Mol. Cancer Ther., 2:835-843; Wu et al., 2003, Telomere dysfunction: a potential cancer predisposition factor.
- Reagents appropriate for each reaction type will be provided in the sample and/or propositioned in the reaction chamber.
- exemplary reagents include antibodies, ligands, enzyme substrates, effectors and the like.
- the methods of the invention may be used for detection, identification and characterization of pathogens.
- a sample contains a heterogeneous mixture of microorganisms (e.g., various bacterial species or strains, viruses, fungi) for which rapid detection and identification would be advantageous.
- clinical (patient) samples often contain small numbers of microorganisms (e.g., bacteria, fungi) or viruses. Rapid characterization would permit earlier administration of appropriate drugs, if necessary.
- the ability to rapidly detect and identify cellular and viral pathogens would be of value in the medical, veterinary, and agricultural fields, as well as in response to actual or suspected bioterrorism and for rapid detection water or food contaminants.
- a relatively small number of cells are available to work with, and, as noted, the cells are often available as a heterogeneous mixture with other cells.
- the method is used to determine whether a patient is infected with methicillin-resistance S. aureus.
- S. aureus can be identified using a bacteria-specific probe (e.g. to a rRNA gene).
- An methicillin resistant strain is distinguished from non-resistant strains based on a characteristic genetic sequence such as an open reading frame (gene or gene segment) or single polynucleotide polymorphism.
- a sample containing bacteria cells is obtained from a patient (e.g., a nose swab containing about 100 bacterial cells) and diluted into a reaction mixture containing nucleic acid primers and other reagents for amplification and detection of target sequences (e.g., PCR reagents, molecular beacons, polymerase, nucleotides, agents that lyse cells for nucleic acid release, etc.).
- target sequences e.g., PCR reagents, molecular beacons, polymerase, nucleotides, agents that lyse cells for nucleic acid release, etc.
- Exemplary PCR primers are described in Huletsky et al., 2004, “New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci.” J Clin Microbiol. 42:1875-84.
- One primer/probe set in the reaction mixture emits a red fluorescence signal in the presence of a S. aureus target sequence found in both resistant and non-resistant stains while the second primer/probe set emits a green fluorescence signal only in the presence of a S. aureus target sequence found in the resistant strain.
- the cells are injected into a MPD and control channels actuated to create separate reaction chambers (e.g., a sample containing about 100 bacterial cells is partitioned into 2000 chambers) all or most of which contain zero or one cell.
- the device is placed on the thermocycler or amplification is otherwise initiated. Detection in a chamber of only a red signal indicates the presence in the sample of non-resistant S. aureus; detection in a chamber of both a red and green signal indicates the presence in the sample of drug resistant S. aureus ; detection or no signal indicates no S. aureus bacteria are present in the sample.
- the method is used for quantization of cells in a heterogeneous population having specific properties.
- a cell population e.g., peripheral blood mononuclear cells (PBMC)
- CTL cytotoxic T lymphocytes
- the antigen reagent can be prepositioned in chambers or combined with cells immediately before partition.
- the proportion or type of cells activated in the presence can be assayed using any of a variety of assays for effector cell activation.
- the precursor population of gag-specific CTL can be quantitated and/or characterized. See, e.g., Koup “Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities” J Exp Med. Dec. 1, 1991;174(6):1593-600.
- biopsies may recover only a few malignant cells in a background of normal cells.
- the methods of the present invention allow the malignant cells to be isolated, identified based on a property (e.g., antigen, mutation or expression pattern) unique to the cancer cell, and then a different property of the cell determined.
- nucleated fetal red blood cells are found at low levels in the blood of pregnant women and are a potential source of information about the fetal genome including any sequences associated with disease or propensity to disease.
- enriched 10,000-fold fetal cells may be less than 0.1% of a sample making analysis by conventional methods difficult.
- Cells from a sample enriched for fetal NRBCs can be partitioned using the methods disclosed herein. Chambers containing fetal cells can be identified using a fetal-specific probe (e.g., a probe specific for the Y chromosome; abundance of RNA encoding fetal forms of hemoglobin) and assayed for several genetic characteristics using a multiplex assay.
- Other examples of rare cells in a background of different cells include, for example, a virally infected cell in a background of uninfected cells, a cell expressing a gene in a background of cells not expressing the gene; and the like.
- the MPD is used to partition a mixed population of cells to detect a property characteristic of a rare cell type in the population, i.e., cells comprising less than about 1%, more often less than about 0.1%, and very often less than about 0.01% of the cells in the population.
- a property characteristic of a rare cell type in the population i.e., cells comprising less than about 1%, more often less than about 0.1%, and very often less than about 0.01% of the cells in the population.
- the methods of the present invention enable analysis of a rare cell without background or interference for other cells.
- the method involves partitioning cells and assaying individual cells for at least two properties at least one of which identifies the rare cell.
- the nucleic acid being analyzed is or includes RNA, and the expression level of specified genes in an individual cell is determined.
- the expression profile for several host genes in a single cell can be correlated with the presence or absence of virus or with viral load.
- Gene expression profiles can also be correlated with cell identity (e.g., different expression profiles for different cells in a sample containing a heterogeneous mixture of cells) or cell response to a stimulus (e.g., the presence of a ligand that binds a cell receptor).
- the reagents that are introduced (or previously spotted) in the reaction sites can include one or all of the following: primer, labeled probe, nucleotides and polymerase.
- Another approach is Ribo-SPIA (see above).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/916,025 US20090317798A1 (en) | 2005-06-02 | 2006-06-02 | Analysis using microfluidic partitioning devices |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68701005P | 2005-06-02 | 2005-06-02 | |
US11/916,025 US20090317798A1 (en) | 2005-06-02 | 2006-06-02 | Analysis using microfluidic partitioning devices |
PCT/US2006/021416 WO2007044091A2 (fr) | 2005-06-02 | 2006-06-02 | Analyse utilisant des dispositifs de separation microfluidiques |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/021416 A-371-Of-International WO2007044091A2 (fr) | 2005-06-02 | 2006-06-02 | Analyse utilisant des dispositifs de separation microfluidiques |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/945,483 Continuation US9364829B2 (en) | 2005-06-02 | 2010-11-12 | Analysis using microfluidic partitioning devices |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090317798A1 true US20090317798A1 (en) | 2009-12-24 |
Family
ID=37943262
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/916,025 Abandoned US20090317798A1 (en) | 2005-06-02 | 2006-06-02 | Analysis using microfluidic partitioning devices |
US12/945,483 Active 2027-02-01 US9364829B2 (en) | 2005-06-02 | 2010-11-12 | Analysis using microfluidic partitioning devices |
US12/945,506 Abandoned US20110143949A1 (en) | 2005-06-02 | 2010-11-12 | Analysis using microfluidic partitioning devices |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/945,483 Active 2027-02-01 US9364829B2 (en) | 2005-06-02 | 2010-11-12 | Analysis using microfluidic partitioning devices |
US12/945,506 Abandoned US20110143949A1 (en) | 2005-06-02 | 2010-11-12 | Analysis using microfluidic partitioning devices |
Country Status (3)
Country | Link |
---|---|
US (3) | US20090317798A1 (fr) |
EP (3) | EP1915618A4 (fr) |
WO (1) | WO2007044091A2 (fr) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080108063A1 (en) * | 2006-04-24 | 2008-05-08 | Fluidigm Corporation | Assay Methods |
US20080220422A1 (en) * | 2006-06-14 | 2008-09-11 | Daniel Shoemaker | Rare cell analysis using sample splitting and dna tags |
US20090257912A1 (en) * | 2006-06-26 | 2009-10-15 | Microsoft Corporation | Self-Sterilizing Input Device |
US20100120038A1 (en) * | 2008-08-26 | 2010-05-13 | Fluidigm Corporation | Assay methods for increased throughput of samples and/or targets |
US20100273219A1 (en) * | 2009-04-02 | 2010-10-28 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US20110236264A1 (en) * | 2010-03-23 | 2011-09-29 | Aditya Rajagopal | Microfluidic device for separating and sorting particles in a fluid medium |
US8048378B2 (en) | 2004-06-07 | 2011-11-01 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US8318430B2 (en) | 2010-01-23 | 2012-11-27 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US20130224751A1 (en) * | 2010-02-12 | 2013-08-29 | Jeffrey Olson | Digital analyte analysis |
US20130237432A1 (en) * | 2010-06-30 | 2013-09-12 | Jian Li | Application of a pcr sequencing method, based on dna barcoding technique and dna incomplete shearing strategy, in hla genotyping |
US20130288229A1 (en) * | 2010-09-17 | 2013-10-31 | Lophius Biosciences Gmbh | METHOD FOR DETECTION, DIFFERENTIATION AND QUANTIFICATION OF T CELL POPULATIONS BY WAY OF REVERSE TRANSCRIPTION QUANTITATIVE REAL TIME PCR (RT-qPCR) TECHNOLOGY |
US20130295567A1 (en) * | 2010-02-12 | 2013-11-07 | Darren Roy Link | Digital analyte analysis |
US20130323732A1 (en) * | 2012-05-21 | 2013-12-05 | Fluidigm Corporation | Single-particle analysis of particle populations |
WO2014151450A1 (fr) * | 2013-03-15 | 2014-09-25 | Siemens Healthcare Diagnostics Inc. | Dispositif de distribution microfluidique |
US20150038356A1 (en) * | 2013-07-25 | 2015-02-05 | Bio-Rad Laboratories, Inc. | Genetic assays |
US9074204B2 (en) | 2011-05-20 | 2015-07-07 | Fluidigm Corporation | Nucleic acid encoding reactions |
US9157116B2 (en) | 2008-02-08 | 2015-10-13 | Fluidigm Corporation | Combinatorial amplification and detection of nucleic acids |
US9364829B2 (en) | 2005-06-02 | 2016-06-14 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US9416776B2 (en) | 2013-03-15 | 2016-08-16 | Siemens Healthcare Diagnostics Inc. | Microfluidic distributing device |
CN107430646A (zh) * | 2015-03-17 | 2017-12-01 | 生物辐射实验室股份有限公司 | 检测基因组编辑 |
US10167509B2 (en) | 2011-02-09 | 2019-01-01 | Bio-Rad Laboratories, Inc. | Analysis of nucleic acids |
US10190163B2 (en) | 2015-02-27 | 2019-01-29 | Fluidigm Corporation | Single cell nucleic acids for high-throughput studies |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US20190374940A1 (en) * | 2018-06-11 | 2019-12-12 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Lateral-flow microfluidic chip and flow velocity control method thereof |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10639597B2 (en) | 2006-05-11 | 2020-05-05 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US10927407B2 (en) | 2006-05-11 | 2021-02-23 | Bio-Rad Laboratories, Inc. | Systems and methods for handling microfluidic droplets |
US10954511B2 (en) * | 2017-06-06 | 2021-03-23 | Zymergen Inc. | HTP genomic engineering platform for improving fungal strains |
US10960397B2 (en) | 2007-04-19 | 2021-03-30 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11028401B2 (en) | 2018-06-06 | 2021-06-08 | Zymergen Inc. | Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production |
US11077415B2 (en) | 2011-02-11 | 2021-08-03 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
US11117113B2 (en) | 2015-12-16 | 2021-09-14 | Fluidigm Corporation | High-level multiplex amplification |
US11168353B2 (en) | 2011-02-18 | 2021-11-09 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11174509B2 (en) | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11187702B2 (en) | 2003-03-14 | 2021-11-30 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US11390917B2 (en) | 2010-02-12 | 2022-07-19 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US11479779B2 (en) | 2020-07-31 | 2022-10-25 | Zymergen Inc. | Systems and methods for high-throughput automated strain generation for non-sporulating fungi |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11635427B2 (en) | 2010-09-30 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
US11679171B2 (en) | 2021-06-08 | 2023-06-20 | Steribin, LLC | Apparatus and method for disinfecting substances as they pass through a pipe |
US11786872B2 (en) | 2004-10-08 | 2023-10-17 | United Kingdom Research And Innovation | Vitro evolution in microfluidic systems |
US11819849B2 (en) | 2007-02-06 | 2023-11-21 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US11898193B2 (en) | 2011-07-20 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Manipulating droplet size |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221654B1 (en) | 1996-09-25 | 2001-04-24 | California Institute Of Technology | Method and apparatus for analysis and sorting of polynucleotides based on size |
US8709153B2 (en) | 1999-06-28 | 2014-04-29 | California Institute Of Technology | Microfludic protein crystallography techniques |
US7306672B2 (en) | 2001-04-06 | 2007-12-11 | California Institute Of Technology | Microfluidic free interface diffusion techniques |
US7459022B2 (en) | 2001-04-06 | 2008-12-02 | California Institute Of Technology | Microfluidic protein crystallography |
US8052792B2 (en) | 2001-04-06 | 2011-11-08 | California Institute Of Technology | Microfluidic protein crystallography techniques |
ATE290166T1 (de) | 1999-06-28 | 2005-03-15 | California Inst Of Techn | Elastisches mikropumpen- oder mikroventilsystem |
US7144616B1 (en) | 1999-06-28 | 2006-12-05 | California Institute Of Technology | Microfabricated elastomeric valve and pump systems |
US20050118073A1 (en) | 2003-11-26 | 2005-06-02 | Fluidigm Corporation | Devices and methods for holding microfluidic devices |
US7867763B2 (en) | 2004-01-25 | 2011-01-11 | Fluidigm Corporation | Integrated chip carriers with thermocycler interfaces and methods of using the same |
US7351376B1 (en) | 2000-06-05 | 2008-04-01 | California Institute Of Technology | Integrated active flux microfluidic devices and methods |
AU2001290879A1 (en) | 2000-09-15 | 2002-03-26 | California Institute Of Technology | Microfabricated crossflow devices and methods |
EP1343973B2 (fr) | 2000-11-16 | 2020-09-16 | California Institute Of Technology | Appareil et procedes pour effectuer des dosages et des criblages a haut rendement |
US7691333B2 (en) | 2001-11-30 | 2010-04-06 | Fluidigm Corporation | Microfluidic device and methods of using same |
JP2005521425A (ja) | 2002-04-01 | 2005-07-21 | フルイディグム コーポレイション | 微小流体粒子分析システム |
US8220494B2 (en) | 2002-09-25 | 2012-07-17 | California Institute Of Technology | Microfluidic large scale integration |
CA2500283A1 (fr) | 2002-09-25 | 2004-04-08 | California Institute Of Technology | Integration microfluidique a grande echelle |
JP5695287B2 (ja) | 2002-10-02 | 2015-04-01 | カリフォルニア インスティテュート オブ テクノロジー | 微小流体の核酸解析 |
US7604965B2 (en) | 2003-04-03 | 2009-10-20 | Fluidigm Corporation | Thermal reaction device and method for using the same |
US8828663B2 (en) | 2005-03-18 | 2014-09-09 | Fluidigm Corporation | Thermal reaction device and method for using the same |
WO2004103563A2 (fr) | 2003-05-20 | 2004-12-02 | Fluidigm Corporation | Procede et systeme pour dispositif microfluidique et son imagerie |
US7407799B2 (en) | 2004-01-16 | 2008-08-05 | California Institute Of Technology | Microfluidic chemostat |
WO2006060748A2 (fr) | 2004-12-03 | 2006-06-08 | California Institute Of Technology | Soupapes a tamis microfluidiques |
EP1838431A4 (fr) | 2004-12-03 | 2012-08-22 | California Inst Of Techn | Dispositifs microfluidiques a circuits de reactions chimiques |
US7883669B2 (en) | 2005-04-20 | 2011-02-08 | Fluidigm Corporation | Analysis engine and database for manipulating parameters for fluidic systems on a chip |
US11111544B2 (en) * | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US20070074972A1 (en) | 2005-09-13 | 2007-04-05 | Fluidigm Corporation | Microfluidic assay devices and methods |
PL1981995T5 (pl) | 2006-02-02 | 2019-10-31 | Univ Leland Stanford Junior | Nieinwazyjne genetyczne badania przesiewowe płodu metodą analizy cyfrowej |
US8460879B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US11237171B2 (en) | 2006-02-21 | 2022-02-01 | Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
US7815868B1 (en) | 2006-02-28 | 2010-10-19 | Fluidigm Corporation | Microfluidic reaction apparatus for high throughput screening |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US8055034B2 (en) | 2006-09-13 | 2011-11-08 | Fluidigm Corporation | Methods and systems for image processing of microfluidic devices |
US8473216B2 (en) | 2006-11-30 | 2013-06-25 | Fluidigm Corporation | Method and program for performing baseline correction of amplification curves in a PCR experiment |
WO2008089493A2 (fr) | 2007-01-19 | 2008-07-24 | Fluidigm Corporation | Dispositifs microfluidiques d'efficacité élevée et de précision élevée et procédés |
US20100151465A1 (en) | 2008-03-27 | 2010-06-17 | Jingyue Ju | Selective Capture and Release of Analytes |
US8016260B2 (en) | 2007-07-19 | 2011-09-13 | Formulatrix, Inc. | Metering assembly and method of dispensing fluid |
HUE030510T2 (hu) | 2007-07-23 | 2017-05-29 | Univ Hong Kong Chinese | Magzati kromoszómális aneuploidia diagnosztizálása genomszekvenálás alkalmazásával |
US20100112590A1 (en) | 2007-07-23 | 2010-05-06 | The Chinese University Of Hong Kong | Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment |
EP2201374B1 (fr) | 2007-08-30 | 2015-10-07 | Trustees Of Tufts College | Procédés pour déterminer la concentration d'un analyte dans une solution |
JP5404638B2 (ja) * | 2007-11-07 | 2014-02-05 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | マイクロ流体デバイスおよびその使用方法 |
CN102056838B (zh) | 2008-04-11 | 2013-07-03 | 弗卢丁公司 | 微流体装置和方法 |
CN104043490A (zh) | 2008-07-25 | 2014-09-17 | 弗卢丁公司 | 用于制造集成流体芯片的方法和系统 |
WO2010017210A1 (fr) | 2008-08-07 | 2010-02-11 | Fluidigm Corporation | Systèmes microfluidique de mélange et de réaction pour un tamisage à efficacité élevée |
US20100112575A1 (en) | 2008-09-20 | 2010-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing |
US8222047B2 (en) | 2008-09-23 | 2012-07-17 | Quanterix Corporation | Ultra-sensitive detection of molecules on single molecule arrays |
US9534255B2 (en) | 2008-12-17 | 2017-01-03 | Life Technologies Corporation | Methods, compositions, and kits for detecting allelic variants |
EA020593B1 (ru) * | 2009-01-13 | 2014-12-30 | Флуидигм Корпорейшн | Анализ нуклеиновых кислот, полученных из единичных клеток |
US8058630B2 (en) | 2009-01-16 | 2011-11-15 | Fluidigm Corporation | Microfluidic devices and methods |
US8100293B2 (en) | 2009-01-23 | 2012-01-24 | Formulatrix, Inc. | Microfluidic dispensing assembly |
JP5805064B2 (ja) | 2009-03-27 | 2015-11-04 | ライフ テクノロジーズ コーポレーション | 対立遺伝子変種を検出するための方法、組成物、およびキット |
US9090663B2 (en) * | 2009-04-21 | 2015-07-28 | The Trustees Of Columbia University In The City Of New York | Systems and methods for the capture and separation of microparticles |
US20120052499A1 (en) * | 2009-05-20 | 2012-03-01 | Advandx, Inc. | Methods For Whole-Cell Analysis Of Gram-Positive Bacteria |
GB2483402B (en) | 2009-06-04 | 2014-04-09 | Lockheed Corp | Multiple-sample microfluidic chip for DNA analysis |
US8551787B2 (en) | 2009-07-23 | 2013-10-08 | Fluidigm Corporation | Microfluidic devices and methods for binary mixing |
SG169918A1 (en) | 2009-10-02 | 2011-04-29 | Fluidigm Corp | Microfluidic devices with removable cover and methods of fabrication and application |
GB0917919D0 (en) | 2009-10-13 | 2009-11-25 | Iti Scotland Ltd | Microfluidic mixer |
WO2011053790A2 (fr) * | 2009-10-30 | 2011-05-05 | Fluidigm Corporation | Dosage de cibles étroitement liées en diagnostic foetal et dosage de détection de coïncidence pour l'analyse génétique |
US9500645B2 (en) | 2009-11-23 | 2016-11-22 | Cyvek, Inc. | Micro-tube particles for microfluidic assays and methods of manufacture |
US9700889B2 (en) | 2009-11-23 | 2017-07-11 | Cyvek, Inc. | Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results |
US9651568B2 (en) | 2009-11-23 | 2017-05-16 | Cyvek, Inc. | Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays |
US9216412B2 (en) | 2009-11-23 | 2015-12-22 | Cyvek, Inc. | Microfluidic devices and methods of manufacture and use |
US9855735B2 (en) | 2009-11-23 | 2018-01-02 | Cyvek, Inc. | Portable microfluidic assay devices and methods of manufacture and use |
US10065403B2 (en) | 2009-11-23 | 2018-09-04 | Cyvek, Inc. | Microfluidic assay assemblies and methods of manufacture |
WO2011063408A1 (fr) | 2009-11-23 | 2011-05-26 | Cyvek, Inc. | Procédé et appareil destiné à réaliser des dosages |
US9759718B2 (en) | 2009-11-23 | 2017-09-12 | Cyvek, Inc. | PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use |
EP2504448B1 (fr) * | 2009-11-25 | 2016-10-19 | Bio-Rad Laboratories, Inc. | Procédés et compositions destinés à détecter un matériel génétique |
WO2011109379A1 (fr) | 2010-03-01 | 2011-09-09 | Quanterix Corporation | Procédés et systèmes pour étendre la plage dynamique dans des dosages pour la détection de molécules ou de particules |
US8415171B2 (en) | 2010-03-01 | 2013-04-09 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
US9678068B2 (en) | 2010-03-01 | 2017-06-13 | Quanterix Corporation | Ultra-sensitive detection of molecules using dual detection methods |
US8236574B2 (en) | 2010-03-01 | 2012-08-07 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
WO2012051529A1 (fr) | 2010-10-15 | 2012-04-19 | Lockheed Martin Corporation | Conception optique microfluidique |
US9353406B2 (en) | 2010-10-22 | 2016-05-31 | Fluidigm Corporation | Universal probe assay methods |
EP2663654A1 (fr) * | 2011-01-14 | 2013-11-20 | Life Technologies Corporation | Procédés, compositions et trousses pour détecter des cellules rares |
US9952237B2 (en) | 2011-01-28 | 2018-04-24 | Quanterix Corporation | Systems, devices, and methods for ultra-sensitive detection of molecules or particles |
US9168531B2 (en) | 2011-03-24 | 2015-10-27 | Fluidigm Corporation | Method for thermal cycling of microfluidic samples |
WO2012142301A2 (fr) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Procédé de détermination d'un protocole de traitement et/ou d'un pronostic de rétablissement d'un patient à la suite d'un traumatisme cérébral |
US9644231B2 (en) | 2011-05-09 | 2017-05-09 | Fluidigm Corporation | Nucleic acid detection using probes |
SG194722A1 (en) | 2011-05-09 | 2013-12-30 | Fluidigm Corp | Probe based nucleic acid detection |
WO2013019714A1 (fr) | 2011-07-29 | 2013-02-07 | The Trustees Of Columbia University In The City Of New York | Capteur d'affinité mems pour surveillance ininterrompue de substances à analyser |
US10466160B2 (en) | 2011-08-01 | 2019-11-05 | Celsee Diagnostics, Inc. | System and method for retrieving and analyzing particles |
US9404864B2 (en) | 2013-03-13 | 2016-08-02 | Denovo Sciences, Inc. | System for imaging captured cells |
CA2842359A1 (fr) | 2011-08-01 | 2013-02-07 | Denovo Sciences | Systeme de capture de cellules et procede d'utilisation |
KR102114734B1 (ko) | 2012-03-08 | 2020-05-25 | 싸이벡, 아이엔씨 | 미세유체 분석 장치용 마이크로튜브 입자 및 제조방법 |
WO2014113502A1 (fr) | 2013-01-15 | 2014-07-24 | Quanterix Corporation | Détection de l'adn ou de l'arn au moyen de matrices de molécules simples et d'autres techniques |
US9752181B2 (en) | 2013-01-26 | 2017-09-05 | Denovo Sciences, Inc. | System and method for capturing and analyzing cells |
EP3540444B1 (fr) | 2013-03-11 | 2022-10-26 | Cue Health Inc. | Systèmes et procédés de détection et de quantification d'analytes |
US10545161B2 (en) | 2013-03-11 | 2020-01-28 | Cue Health Inc. | Systems and methods for detection and quantification of analytes |
US9623409B2 (en) | 2013-03-11 | 2017-04-18 | Cue Inc. | Cartridges, kits, and methods for enhanced mixing for detection and quantification of analytes |
US9707562B2 (en) | 2013-03-13 | 2017-07-18 | Denovo Sciences, Inc. | System for capturing and analyzing cells |
EP2970849B1 (fr) * | 2013-03-15 | 2019-08-21 | Fluidigm Corporation | Procédés et dispositifs pour l'analyse de combinaisons multicellulaires définies |
US10391490B2 (en) | 2013-05-31 | 2019-08-27 | Celsee Diagnostics, Inc. | System and method for isolating and analyzing cells |
US9856535B2 (en) | 2013-05-31 | 2018-01-02 | Denovo Sciences, Inc. | System for isolating cells |
DE102013019653B3 (de) * | 2013-11-23 | 2014-05-08 | Thomas Taeger | Vorrichtung und Verfahren, um logarithmischen Testaufwand bei Reihentestung flüssiger oder gasförmiger Proben zu erreichen |
DE102014200468A1 (de) * | 2014-01-14 | 2015-07-16 | Robert Bosch Gmbh | Mikrofluidisches System sowie Verfahren zum Vorbereiten und Analysieren einer Zellen enthaltenden Probe biologischen Materials |
USD745423S1 (en) | 2014-05-12 | 2015-12-15 | Cue Inc. | Automated analyzer test cartridge and sample collection device for analyte detection |
WO2016022696A1 (fr) | 2014-08-05 | 2016-02-11 | The Trustees Of Columbia University In The City Of New York | Procédé d'isolement d'aptamères pour détecter une maladie résiduelle minimale |
DE102014221309A1 (de) | 2014-10-21 | 2016-04-21 | Robert Bosch Gmbh | Mikrofluidisches System sowie Verfahren zum Analysieren einer Probenlösung und Verfahren zum Herstellen eines mikrofluidischen Systems zum Analysieren |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
US10385387B2 (en) | 2015-04-20 | 2019-08-20 | Pacific Biosciences Of California, Inc. | Methods for selectively amplifying and tagging nucleic acids |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
CN108136391B (zh) | 2015-07-17 | 2021-01-26 | 克忧健康公司 | 用于增强检测和分析物定量的系统及方法 |
US10228367B2 (en) | 2015-12-01 | 2019-03-12 | ProteinSimple | Segmented multi-use automated assay cartridge |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
WO2018140540A1 (fr) | 2017-01-25 | 2018-08-02 | Cue Health Inc. | Systèmes et procédés pour la détection améliorée et la quantification de substances à analyser |
AU2018323449B2 (en) | 2017-08-29 | 2020-09-03 | Bio-Rad Laboratories, Inc. | System and method for isolating and analyzing cells |
US10633693B1 (en) | 2019-04-16 | 2020-04-28 | Celsee Diagnostics, Inc. | System and method for leakage control in a particle capture system |
US11273439B2 (en) | 2019-05-07 | 2022-03-15 | Bio-Rad Laboratories, Inc. | System and method for target material retrieval from microwells |
CA3138881A1 (fr) | 2019-05-07 | 2020-11-12 | Bio-Rad Laboratories, Inc. | Systeme et procede de traitement automatique de cellules individuelles |
AU2020290981B2 (en) | 2019-06-14 | 2024-03-07 | Bio-Rad Laboratories, Inc. | System and method for automated single cell processing and analyses |
US11504719B2 (en) | 2020-03-12 | 2022-11-22 | Bio-Rad Laboratories, Inc. | System and method for receiving and delivering a fluid for sample processing |
US20220259680A1 (en) * | 2021-02-16 | 2022-08-18 | Bio-Rad Laboratories, Inc. | SARS CoV-2 INFECTIVITY DETERMINATION ASSAY |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6045993A (en) * | 1998-05-30 | 2000-04-04 | Visible Genetics Inc. | Method, reagent and kit for genotyping of human papillomavirus |
US20020160404A1 (en) * | 1998-03-26 | 2002-10-31 | Roche Molecular Systems, Inc. | Method of primer-extension preamplification PCR |
US20030138829A1 (en) * | 2001-11-30 | 2003-07-24 | Fluidigm Corp. | Microfluidic device and methods of using same |
US20030180715A1 (en) * | 2001-08-08 | 2003-09-25 | Sharon Kemp | Methods and means for assessing HIV envelope inhibitor therapy |
US20030228613A1 (en) * | 2001-10-15 | 2003-12-11 | Carole Bornarth | Nucleic acid amplification |
US20040110166A1 (en) * | 2002-03-07 | 2004-06-10 | Macevicz Stephen C. | Genome-wide scanning of genetic polymorphisms |
US20040137470A1 (en) * | 2002-03-01 | 2004-07-15 | Dhallan Ravinder S. | Methods for detection of genetic disorders |
US20060053503A1 (en) * | 2004-07-30 | 2006-03-09 | Ut-Battelle, Llc | Cranial and vertebral defects associated with loss-of-function of Nell |
US20060141518A1 (en) * | 2004-03-24 | 2006-06-29 | Lao Kai Q | Detection of gene expression |
US20080108063A1 (en) * | 2006-04-24 | 2008-05-08 | Fluidigm Corporation | Assay Methods |
US20080223721A1 (en) * | 2007-01-19 | 2008-09-18 | Fluidigm Corporation | High Efficiency and High Precision Microfluidic Devices and Methods |
US20090257920A1 (en) * | 2008-04-11 | 2009-10-15 | Fluidigm Corporation | Multilevel microfluidic systems and methods |
US20100120077A1 (en) * | 2002-04-01 | 2010-05-13 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US20100178655A1 (en) * | 2009-01-13 | 2010-07-15 | Fluidigm Corporation | Single-cell nucleic acid analysis |
US20100203538A1 (en) * | 2009-01-28 | 2010-08-12 | Fluidigm Corporation | Determination of copy number differences by amplification |
US20100273219A1 (en) * | 2009-04-02 | 2010-10-28 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US7887753B2 (en) * | 2000-11-16 | 2011-02-15 | California Institute Of Technology | Apparatus and methods for conducting assays and high throughput screening |
US20110129841A1 (en) * | 2005-06-02 | 2011-06-02 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20110257039A1 (en) * | 2005-12-06 | 2011-10-20 | Life Technologies Corporation | Reverse transcription primers and methods of design |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US556773A (en) * | 1896-03-24 | Block system for railways | ||
DE4038804A1 (de) | 1990-10-09 | 1992-04-16 | Boehringer Mannheim Gmbh | Verfahren zur genus- oder/und spezies-spezifischen detektion von bakterien in einer probenfluessigkeit |
US5272081A (en) * | 1982-05-10 | 1993-12-21 | Bar-Ilan University | System and methods for cell selection |
US4508625A (en) * | 1982-10-18 | 1985-04-02 | Graham Marshall D | Magnetic separation using chelated magnetic ions |
US4822733A (en) | 1985-05-28 | 1989-04-18 | Amoco Corporation | Lifetime-resolved assay procedures |
US5164598A (en) | 1985-08-05 | 1992-11-17 | Biotrack | Capillary flow device |
US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
US5641628A (en) * | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
JPH05507404A (ja) | 1990-04-23 | 1993-10-28 | セルプロ インコーポレイティド | 母体血液からの胎児細胞の富化のための方法 |
WO1992004458A1 (fr) | 1990-09-11 | 1992-03-19 | The Brookdale Hospital Medical Center | Procede de depistage de la resistance aux medicaments |
AU2765992A (en) * | 1991-10-03 | 1993-05-03 | Indiana University Foundation | Method for screening for alzheimer's disease |
EP0576842B1 (fr) | 1992-06-11 | 2002-10-16 | MERCK PATENT GmbH | Méthode et moyens pour détecter listeria |
US5556773A (en) | 1993-08-06 | 1996-09-17 | Yourno; Joseph | Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
US5622821A (en) | 1994-06-29 | 1997-04-22 | The Regents Of The University Of California | Luminescent lanthanide chelates and methods of use |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
US5750339A (en) | 1994-11-30 | 1998-05-12 | Thomas Jefferson University | Methods for identifying fetal cells |
JP3439221B2 (ja) | 1995-12-18 | 2003-08-25 | ワシントン ユニヴァーシティ | 蛍光共鳴エネルギー移動を利用する核酸分析方法 |
US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
IT1294964B1 (it) | 1996-07-12 | 1999-04-23 | Domenico Valerio | Isolamento e cultura di cellule fetali dal sangue periferico materno |
US6300077B1 (en) | 1996-08-14 | 2001-10-09 | Exact Sciences Corporation | Methods for the detection of nucleic acids |
US6100029A (en) | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
WO1998010267A1 (fr) * | 1996-09-04 | 1998-03-12 | Technical University Of Denmark | Systeme a microdebit pour separation et analyse de particules |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
US5965375A (en) | 1997-04-04 | 1999-10-12 | Biosite Diagnostics | Diagnostic tests and kits for Clostridium difficile |
US6143496A (en) * | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
US6368871B1 (en) | 1997-08-13 | 2002-04-09 | Cepheid | Non-planar microstructures for manipulation of fluid samples |
ATE469982T1 (de) | 1998-02-04 | 2010-06-15 | Life Technologies Corp | Bestimmung des genotyps eines amplifikationsproduktes an mehreren allelen stellen |
US6387652B1 (en) | 1998-04-15 | 2002-05-14 | U.S. Environmental Protection Agency | Method of identifying and quantifying specific fungi and bacteria |
US20030022207A1 (en) | 1998-10-16 | 2003-01-30 | Solexa, Ltd. | Arrayed polynucleotides and their use in genome analysis |
US6632642B1 (en) | 1998-08-11 | 2003-10-14 | Asahi Breweries, Ltd. | Genes for detecting bacteria and detection method by using the same |
US6656697B1 (en) | 1998-09-28 | 2003-12-02 | Lifescan, Inc. | Diagnostics based on tetrazolium compounds |
US6511967B1 (en) | 1999-04-23 | 2003-01-28 | The General Hospital Corporation | Use of an internalizing transferrin receptor to image transgene expression |
US6899137B2 (en) | 1999-06-28 | 2005-05-31 | California Institute Of Technology | Microfabricated elastomeric valve and pump systems |
ATE290166T1 (de) | 1999-06-28 | 2005-03-15 | California Inst Of Techn | Elastisches mikropumpen- oder mikroventilsystem |
US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
US6723505B1 (en) | 1999-08-13 | 2004-04-20 | Nye Colifast As | Method for identification of the indicators of contamination in liquid samples |
US6613581B1 (en) | 1999-08-26 | 2003-09-02 | Caliper Technologies Corp. | Microfluidic analytic detection assays, devices, and integrated systems |
EP1218542B1 (fr) | 1999-09-13 | 2004-03-24 | Nugen Technologies, Inc. | Procedes et compositions utiles pour l'amplification isothermique lineaire de sequences de polynucleotides |
US6692918B2 (en) | 1999-09-13 | 2004-02-17 | Nugen Technologies, Inc. | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
WO2001055454A1 (fr) | 2000-01-28 | 2001-08-02 | Althea Technologies, Inc. | Procedes d'analyse de l'expression genique |
US7306904B2 (en) | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
EP1309863A1 (fr) | 2000-08-08 | 2003-05-14 | Aviva Biosciences Corporation | Techniques de manipulations de fragments dans des systemes microfluidiques |
US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
CA2428757A1 (fr) * | 2000-11-15 | 2002-07-18 | Roche Diagnostics Corporation | Methodes et reactifs permettant d'identifier des cellules embryonnaires rares dans le systeme circulatoire maternel |
AU2002252279B2 (en) | 2001-03-09 | 2005-05-12 | Nugen Technologies, Inc. | Methods and compositions for amplification of RNA sequences |
WO2002081729A2 (fr) | 2001-04-06 | 2002-10-17 | California Institute Of Technology | Amplification d'acide nucleique au moyen de dispositifs microfluidiques |
US20020155587A1 (en) * | 2001-04-20 | 2002-10-24 | Sequenom, Inc. | System and method for testing a biological sample |
FR2824144B1 (fr) | 2001-04-30 | 2004-09-17 | Metagenex S A R L | Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel |
US20020166760A1 (en) | 2001-05-11 | 2002-11-14 | Prentiss Mara G. | Micromagentic systems and methods for microfluidics |
US7993908B2 (en) | 2001-07-17 | 2011-08-09 | Parsortix, Inc. | Microstructure for particle and cell separation, identification, sorting, and manipulation |
US6783928B2 (en) | 2001-07-17 | 2004-08-31 | Georgi Hvichia | Microstructures for cell proliferation assays and semen analysis |
US6927028B2 (en) * | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
US7166443B2 (en) * | 2001-10-11 | 2007-01-23 | Aviva Biosciences Corporation | Methods, compositions, and automated systems for separating rare cells from fluid samples |
JP2005509871A (ja) | 2001-11-20 | 2005-04-14 | エグザクト サイエンシーズ コーポレイション | 自動化サンプル調製方法および装置 |
US7691333B2 (en) * | 2001-11-30 | 2010-04-06 | Fluidigm Corporation | Microfluidic device and methods of using same |
US7312085B2 (en) * | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US7727720B2 (en) * | 2002-05-08 | 2010-06-01 | Ravgen, Inc. | Methods for detection of genetic disorders |
US7442506B2 (en) | 2002-05-08 | 2008-10-28 | Ravgen, Inc. | Methods for detection of genetic disorders |
US20060086309A1 (en) * | 2002-06-24 | 2006-04-27 | Fluiding Corporation | Recirculating fluidic network and methods for using the same |
US7106905B2 (en) | 2002-08-23 | 2006-09-12 | Hewlett-Packard Development Company, L.P. | Systems and methods for processing text-based electronic documents |
US8220494B2 (en) | 2002-09-25 | 2012-07-17 | California Institute Of Technology | Microfluidic large scale integration |
EP2359689B1 (fr) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Dispositif microfluidique pour la séparation de cellules et usage du dispositif |
EP1585583B1 (fr) | 2002-10-23 | 2010-04-07 | The Trustees of Princeton University | Procede de separation continue de particules faisant appel a des reseaux d'obstacles alignes de maniere asymetrique par rapport a des champs |
US7704687B2 (en) | 2002-11-15 | 2010-04-27 | The Johns Hopkins University | Digital karyotyping |
JPWO2004051231A1 (ja) | 2002-11-29 | 2006-04-06 | 日本電気株式会社 | 分離装置および分離方法 |
EP1583846B1 (fr) | 2003-01-17 | 2011-11-16 | The Chinese University Of Hong Kong | Arnm circulant utilises comme marqueurs diagnostiques pour des troubles de la grossesse |
AU2003901671A0 (en) | 2003-04-02 | 2003-05-01 | The University Of Adelaide | Comparative genomic hybridization |
US20050145496A1 (en) * | 2003-04-03 | 2005-07-07 | Federico Goodsaid | Thermal reaction device and method for using the same |
US7476363B2 (en) * | 2003-04-03 | 2009-01-13 | Fluidigm Corporation | Microfluidic devices and methods of using same |
WO2004089810A2 (fr) * | 2003-04-03 | 2004-10-21 | Fluidigm Corp. | Dispositifs microfluidiques et leurs procedes d'utilisation |
US7604965B2 (en) | 2003-04-03 | 2009-10-20 | Fluidigm Corporation | Thermal reaction device and method for using the same |
WO2004113877A1 (fr) | 2003-06-13 | 2004-12-29 | The General Hospital Corporation | Systemes microfluidiques d'elimination basee sur la taille de globules rouges et de plaquettes du sang |
EP2354253A3 (fr) | 2003-09-05 | 2011-11-16 | Trustees of Boston University | Procede de diagnostic prenatal non effractif |
CN1997691B (zh) | 2003-09-23 | 2011-07-20 | 北卡罗来纳大学查珀尔希尔分校 | 光固化的全氟聚醚用作微流体器件中的新材料 |
EP1524321B2 (fr) | 2003-10-16 | 2014-07-23 | Sequenom, Inc. | Détection non invasive de traits génétiques létaux |
WO2005039389A2 (fr) | 2003-10-22 | 2005-05-06 | 454 Corporation | Caryotypage base sur des séquences |
US7632640B2 (en) | 2003-12-08 | 2009-12-15 | The Clinic For Special Children | Association of TSPYL polymorphisms with SIDDT syndrome |
CN101189271A (zh) | 2004-02-13 | 2008-05-28 | 北卡罗来纳大学查珀尔希尔分校 | 制造微流体设备的功能材料和新型方法 |
US20060046258A1 (en) * | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
US7468249B2 (en) | 2004-05-05 | 2008-12-23 | Biocept, Inc. | Detection of chromosomal disorders |
US20050287611A1 (en) | 2004-05-07 | 2005-12-29 | Nugent C T Iv | MHC bridging system for detecting CTL-mediated lysis of antigen presenting cells |
US20060051265A1 (en) * | 2004-09-08 | 2006-03-09 | Health Research, Inc. | Apparatus and method for sorting microstructures in a fluid medium |
CN101137761B (zh) | 2005-03-18 | 2010-12-08 | 香港中文大学 | 产前诊断和监测的标记 |
US7645576B2 (en) | 2005-03-18 | 2010-01-12 | The Chinese University Of Hong Kong | Method for the detection of chromosomal aneuploidies |
US20060223178A1 (en) | 2005-04-05 | 2006-10-05 | Tom Barber | Devices and methods for magnetic enrichment of cells and other particles |
US20070059680A1 (en) | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
US20070059719A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Business methods for prenatal Diagnosis |
US20070059781A1 (en) | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
US20070059774A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
US20070059716A1 (en) | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
PL1981995T5 (pl) * | 2006-02-02 | 2019-10-31 | Univ Leland Stanford Junior | Nieinwazyjne genetyczne badania przesiewowe płodu metodą analizy cyfrowej |
DK1996728T3 (da) | 2006-02-28 | 2011-08-15 | Univ Louisville Res Found | Detektering af føtale chromosomale abnormiteter under anvendelse af tandem-enkeltnukleotid-polymorfismer |
US20080038733A1 (en) | 2006-03-28 | 2008-02-14 | Baylor College Of Medicine | Screening for down syndrome |
EP2040843B1 (fr) * | 2006-06-01 | 2020-02-26 | The Trustees of Princeton University | Appareil pour une séparation continue de particules |
WO2008111990A1 (fr) | 2006-06-14 | 2008-09-18 | Cellpoint Diagnostics, Inc. | Analyse de cellules rares par division d'échantillon et utilisation de marqueurs d'adn |
EP2029779A4 (fr) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | Utilisation de génotypage snp fortement parallèle pour diagnostic fétal |
WO2009035447A1 (fr) * | 2006-06-14 | 2009-03-19 | Living Microsystems, Inc. | Diagnostic d'anomalies fœtales par une analyse par hybridation génomique comparative |
US8137912B2 (en) * | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) * | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2589668A1 (fr) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Analyse de cellules rares utilisant la division d'échantillons et les marqueurs d'ADN |
JP2009540802A (ja) * | 2006-06-16 | 2009-11-26 | セクエノム, インコーポレイテッド | サンプルからの核酸を増幅、検出および定量するための方法および組成物 |
HUE030510T2 (hu) * | 2007-07-23 | 2017-05-29 | Univ Hong Kong Chinese | Magzati kromoszómális aneuploidia diagnosztizálása genomszekvenálás alkalmazásával |
US20090053719A1 (en) | 2007-08-03 | 2009-02-26 | The Chinese University Of Hong Kong | Analysis of nucleic acids by digital pcr |
-
2006
- 2006-06-02 US US11/916,025 patent/US20090317798A1/en not_active Abandoned
- 2006-06-02 WO PCT/US2006/021416 patent/WO2007044091A2/fr active Application Filing
- 2006-06-02 EP EP06836075A patent/EP1915618A4/fr not_active Withdrawn
- 2006-06-02 EP EP13181405.5A patent/EP2703499A1/fr not_active Ceased
- 2006-06-02 EP EP11196269A patent/EP2477029A1/fr not_active Withdrawn
-
2010
- 2010-11-12 US US12/945,483 patent/US9364829B2/en active Active
- 2010-11-12 US US12/945,506 patent/US20110143949A1/en not_active Abandoned
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020160404A1 (en) * | 1998-03-26 | 2002-10-31 | Roche Molecular Systems, Inc. | Method of primer-extension preamplification PCR |
US6045993A (en) * | 1998-05-30 | 2000-04-04 | Visible Genetics Inc. | Method, reagent and kit for genotyping of human papillomavirus |
US7887753B2 (en) * | 2000-11-16 | 2011-02-15 | California Institute Of Technology | Apparatus and methods for conducting assays and high throughput screening |
US20030180715A1 (en) * | 2001-08-08 | 2003-09-25 | Sharon Kemp | Methods and means for assessing HIV envelope inhibitor therapy |
US20030228613A1 (en) * | 2001-10-15 | 2003-12-11 | Carole Bornarth | Nucleic acid amplification |
US20030138829A1 (en) * | 2001-11-30 | 2003-07-24 | Fluidigm Corp. | Microfluidic device and methods of using same |
US20040137470A1 (en) * | 2002-03-01 | 2004-07-15 | Dhallan Ravinder S. | Methods for detection of genetic disorders |
US20040110166A1 (en) * | 2002-03-07 | 2004-06-10 | Macevicz Stephen C. | Genome-wide scanning of genetic polymorphisms |
US20100120077A1 (en) * | 2002-04-01 | 2010-05-13 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US20060141518A1 (en) * | 2004-03-24 | 2006-06-29 | Lao Kai Q | Detection of gene expression |
US20060053503A1 (en) * | 2004-07-30 | 2006-03-09 | Ut-Battelle, Llc | Cranial and vertebral defects associated with loss-of-function of Nell |
US20110143949A1 (en) * | 2005-06-02 | 2011-06-16 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20110129841A1 (en) * | 2005-06-02 | 2011-06-02 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20110257039A1 (en) * | 2005-12-06 | 2011-10-20 | Life Technologies Corporation | Reverse transcription primers and methods of design |
US20080108063A1 (en) * | 2006-04-24 | 2008-05-08 | Fluidigm Corporation | Assay Methods |
US20080223721A1 (en) * | 2007-01-19 | 2008-09-18 | Fluidigm Corporation | High Efficiency and High Precision Microfluidic Devices and Methods |
US20090257920A1 (en) * | 2008-04-11 | 2009-10-15 | Fluidigm Corporation | Multilevel microfluidic systems and methods |
US20100178655A1 (en) * | 2009-01-13 | 2010-07-15 | Fluidigm Corporation | Single-cell nucleic acid analysis |
US20100203538A1 (en) * | 2009-01-28 | 2010-08-12 | Fluidigm Corporation | Determination of copy number differences by amplification |
US20100273219A1 (en) * | 2009-04-02 | 2010-10-28 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
Non-Patent Citations (4)
Title |
---|
C1 Single-Cell AutoPrep System, Fluidigm Corporation, 2012 * |
Laboratory Talk, "Isolation and processing of individual cells", June 21, 2012 * |
Lin, Z. et al., PNAS USA, vol. 93, pp. 2582-2587 (1996) * |
White, A.K. et al., PNAS USA, vol. 108, pp. 13999-14004 plus supplement (August 2011) * |
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11187702B2 (en) | 2003-03-14 | 2021-11-30 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US10745748B2 (en) | 2004-06-07 | 2020-08-18 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US9234237B2 (en) | 2004-06-07 | 2016-01-12 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US8721968B2 (en) | 2004-06-07 | 2014-05-13 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US8926905B2 (en) | 2004-06-07 | 2015-01-06 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US9663821B2 (en) | 2004-06-07 | 2017-05-30 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US8048378B2 (en) | 2004-06-07 | 2011-11-01 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US10106846B2 (en) | 2004-06-07 | 2018-10-23 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US8512640B2 (en) | 2004-06-07 | 2013-08-20 | Fluidigm Corporation | Optical lens system and method for microfluidic devices |
US11786872B2 (en) | 2004-10-08 | 2023-10-17 | United Kingdom Research And Innovation | Vitro evolution in microfluidic systems |
US9364829B2 (en) | 2005-06-02 | 2016-06-14 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20080108063A1 (en) * | 2006-04-24 | 2008-05-08 | Fluidigm Corporation | Assay Methods |
US9090934B2 (en) | 2006-04-24 | 2015-07-28 | Fluidigm Corporation | Methods for detection and quantification of nucleic acid or protein targets in a sample |
US9644235B2 (en) | 2006-04-24 | 2017-05-09 | Fluidigm Corporation | Methods for detection and quantification of nucleic acid or protein targets in a sample |
US8828661B2 (en) * | 2006-04-24 | 2014-09-09 | Fluidigm Corporation | Methods for detection and quantification of nucleic acid or protein targets in a sample |
US10927407B2 (en) | 2006-05-11 | 2021-02-23 | Bio-Rad Laboratories, Inc. | Systems and methods for handling microfluidic droplets |
US10639597B2 (en) | 2006-05-11 | 2020-05-05 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US11351510B2 (en) | 2006-05-11 | 2022-06-07 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US11674176B2 (en) | 2006-06-14 | 2023-06-13 | Verinata Health, Inc | Fetal aneuploidy detection by sequencing |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20080220422A1 (en) * | 2006-06-14 | 2008-09-11 | Daniel Shoemaker | Rare cell analysis using sample splitting and dna tags |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US8283639B2 (en) * | 2006-06-26 | 2012-10-09 | Microsoft Corporation | Self-sterilizing input device |
US20090257912A1 (en) * | 2006-06-26 | 2009-10-15 | Microsoft Corporation | Self-Sterilizing Input Device |
US11819849B2 (en) | 2007-02-06 | 2023-11-21 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US11224876B2 (en) | 2007-04-19 | 2022-01-18 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10960397B2 (en) | 2007-04-19 | 2021-03-30 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11618024B2 (en) | 2007-04-19 | 2023-04-04 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US9157116B2 (en) | 2008-02-08 | 2015-10-13 | Fluidigm Corporation | Combinatorial amplification and detection of nucleic acids |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11596908B2 (en) | 2008-07-18 | 2023-03-07 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11534727B2 (en) | 2008-07-18 | 2022-12-27 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US8697363B2 (en) | 2008-08-26 | 2014-04-15 | Fluidigm Corporation | Methods for detecting multiple target nucleic acids in multiple samples by use nucleotide tags |
US20100120038A1 (en) * | 2008-08-26 | 2010-05-13 | Fluidigm Corporation | Assay methods for increased throughput of samples and/or targets |
US20100273219A1 (en) * | 2009-04-02 | 2010-10-28 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US10344318B2 (en) | 2009-04-02 | 2019-07-09 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US8691509B2 (en) | 2009-04-02 | 2014-04-08 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US9677119B2 (en) | 2009-04-02 | 2017-06-13 | Fluidigm Corporation | Multi-primer amplification method for tagging of target nucleic acids |
US11795494B2 (en) | 2009-04-02 | 2023-10-24 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
US10718020B2 (en) | 2010-01-23 | 2020-07-21 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US9493831B2 (en) | 2010-01-23 | 2016-11-15 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US8318430B2 (en) | 2010-01-23 | 2012-11-27 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US9127310B2 (en) * | 2010-02-12 | 2015-09-08 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) * | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US20130224751A1 (en) * | 2010-02-12 | 2013-08-29 | Jeffrey Olson | Digital analyte analysis |
US10808279B2 (en) | 2010-02-12 | 2020-10-20 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US11390917B2 (en) | 2010-02-12 | 2022-07-19 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US20130295567A1 (en) * | 2010-02-12 | 2013-11-07 | Darren Roy Link | Digital analyte analysis |
US9228229B2 (en) * | 2010-02-12 | 2016-01-05 | Raindance Technologies, Inc. | Digital analyte analysis |
US11254968B2 (en) | 2010-02-12 | 2022-02-22 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US8496889B2 (en) * | 2010-03-23 | 2013-07-30 | California Institute Of Technology | Microfluidic device for separating and sorting particles in a fluid medium |
US20110236264A1 (en) * | 2010-03-23 | 2011-09-29 | Aditya Rajagopal | Microfluidic device for separating and sorting particles in a fluid medium |
US9957564B2 (en) * | 2010-06-30 | 2018-05-01 | Bgi Genomics Co., Ltd. | Application of a PCR sequencing method, based on DNA barcoding technique and DNA incomplete shearing strategy, in HLA genotyping |
US20130237432A1 (en) * | 2010-06-30 | 2013-09-12 | Jian Li | Application of a pcr sequencing method, based on dna barcoding technique and dna incomplete shearing strategy, in hla genotyping |
US9733246B2 (en) * | 2010-09-17 | 2017-08-15 | Lophius Biosciences Gmbh | Method for detection, differentiation and quantification of T cell populations by way of reverse transcription quantitative real time PCR (RT-qPCR) technology |
US20130288229A1 (en) * | 2010-09-17 | 2013-10-31 | Lophius Biosciences Gmbh | METHOD FOR DETECTION, DIFFERENTIATION AND QUANTIFICATION OF T CELL POPULATIONS BY WAY OF REVERSE TRANSCRIPTION QUANTITATIVE REAL TIME PCR (RT-qPCR) TECHNOLOGY |
US11635427B2 (en) | 2010-09-30 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
US11499181B2 (en) | 2011-02-09 | 2022-11-15 | Bio-Rad Laboratories, Inc. | Analysis of nucleic acids |
US10167509B2 (en) | 2011-02-09 | 2019-01-01 | Bio-Rad Laboratories, Inc. | Analysis of nucleic acids |
US11077415B2 (en) | 2011-02-11 | 2021-08-03 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
US11768198B2 (en) | 2011-02-18 | 2023-09-26 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11747327B2 (en) | 2011-02-18 | 2023-09-05 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11168353B2 (en) | 2011-02-18 | 2021-11-09 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US9074204B2 (en) | 2011-05-20 | 2015-07-07 | Fluidigm Corporation | Nucleic acid encoding reactions |
US10501786B2 (en) | 2011-05-20 | 2019-12-10 | Fluidigm Corporation | Nucleic acid encoding reactions |
US11754499B2 (en) | 2011-06-02 | 2023-09-12 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US11898193B2 (en) | 2011-07-20 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Manipulating droplet size |
US20130323732A1 (en) * | 2012-05-21 | 2013-12-05 | Fluidigm Corporation | Single-particle analysis of particle populations |
CN104471077A (zh) * | 2012-05-21 | 2015-03-25 | 富鲁达公司 | 颗粒群的单颗粒分析 |
US9840732B2 (en) * | 2012-05-21 | 2017-12-12 | Fluidigm Corporation | Single-particle analysis of particle populations |
KR20150130523A (ko) * | 2013-03-15 | 2015-11-23 | 지멘스 헬쓰케어 다이아그노스틱스 인크. | 미세유체 분배 장치 |
US10105701B2 (en) | 2013-03-15 | 2018-10-23 | Siemens Healthcare Diagnostics Inc. | Microfluidic distributing device |
WO2014151450A1 (fr) * | 2013-03-15 | 2014-09-25 | Siemens Healthcare Diagnostics Inc. | Dispositif de distribution microfluidique |
CN105026932A (zh) * | 2013-03-15 | 2015-11-04 | 西门子医疗保健诊断公司 | 微流控分配设备 |
US9416776B2 (en) | 2013-03-15 | 2016-08-16 | Siemens Healthcare Diagnostics Inc. | Microfluidic distributing device |
KR101653701B1 (ko) | 2013-03-15 | 2016-09-02 | 지멘스 헬쓰케어 다이아그노스틱스 인크. | 미세유체 분배 장치 |
US20150038356A1 (en) * | 2013-07-25 | 2015-02-05 | Bio-Rad Laboratories, Inc. | Genetic assays |
US9944998B2 (en) * | 2013-07-25 | 2018-04-17 | Bio-Rad Laboratories, Inc. | Genetic assays |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US11174509B2 (en) | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US10190163B2 (en) | 2015-02-27 | 2019-01-29 | Fluidigm Corporation | Single cell nucleic acids for high-throughput studies |
US10954560B2 (en) | 2015-02-27 | 2021-03-23 | Fluidigm Corporation | Single-cell nucleic acids for high-throughput studies |
CN107430646B (zh) * | 2015-03-17 | 2021-10-22 | 生物辐射实验室股份有限公司 | 检测基因组编辑 |
CN107430646A (zh) * | 2015-03-17 | 2017-12-01 | 生物辐射实验室股份有限公司 | 检测基因组编辑 |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
US11117113B2 (en) | 2015-12-16 | 2021-09-14 | Fluidigm Corporation | High-level multiplex amplification |
US11857940B2 (en) | 2015-12-16 | 2024-01-02 | Fluidigm Corporation | High-level multiplex amplification |
US11180753B2 (en) | 2017-06-06 | 2021-11-23 | Zymergen Inc. | HTP genomic engineering platform for improving fungal strains |
US11242524B2 (en) | 2017-06-06 | 2022-02-08 | Zymergen Inc. | HTP genomic engineering platform for improving fungal strains |
US10954511B2 (en) * | 2017-06-06 | 2021-03-23 | Zymergen Inc. | HTP genomic engineering platform for improving fungal strains |
US11299741B2 (en) | 2018-06-06 | 2022-04-12 | Zymergen Inc. | Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production |
US11028401B2 (en) | 2018-06-06 | 2021-06-08 | Zymergen Inc. | Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production |
US20190374940A1 (en) * | 2018-06-11 | 2019-12-12 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Lateral-flow microfluidic chip and flow velocity control method thereof |
US11479779B2 (en) | 2020-07-31 | 2022-10-25 | Zymergen Inc. | Systems and methods for high-throughput automated strain generation for non-sporulating fungi |
US11679171B2 (en) | 2021-06-08 | 2023-06-20 | Steribin, LLC | Apparatus and method for disinfecting substances as they pass through a pipe |
Also Published As
Publication number | Publication date |
---|---|
US9364829B2 (en) | 2016-06-14 |
WO2007044091A3 (fr) | 2007-11-15 |
WO2007044091A2 (fr) | 2007-04-19 |
US20110129841A1 (en) | 2011-06-02 |
EP2477029A1 (fr) | 2012-07-18 |
EP1915618A2 (fr) | 2008-04-30 |
EP2703499A1 (fr) | 2014-03-05 |
EP1915618A4 (fr) | 2009-09-30 |
US20110143949A1 (en) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9364829B2 (en) | Analysis using microfluidic partitioning devices | |
US20220154248A1 (en) | Combined multiple-displacement amplification and pcr in an emulsion microdroplet | |
US8338166B2 (en) | Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture | |
EP3253910B1 (fr) | Amplification d'acides nucléiques en émulsions multiples | |
EP2340890B1 (fr) | Procédé pour réaliser PCR numérique | |
US20180073051A1 (en) | Thermal reaction device and method for using the same | |
US8828663B2 (en) | Thermal reaction device and method for using the same | |
US7691333B2 (en) | Microfluidic device and methods of using same | |
EP2360234B1 (fr) | Dispositif microfluidique et methode d'utilisation | |
EP2371453A1 (fr) | Dispositif microfluidique | |
JP2006521829A5 (fr) | ||
US20180243741A1 (en) | Thermal reaction device and method for using the same | |
Ganguly et al. | A Poisson-Independent Approach to Precision Nucleic Acid Quantification in Microdroplets | |
Thompson | Single-Cell Molecular Profiling of Nucleic Acids in the Microfluidic Self-Digitization Chip | |
Sundberg | Microfluidic techniques for DNA melting analysis and digital polymerase chain reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FLUIDIGM CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEID, CHRISTIAN A.;DARIDON, ANTOINE;REEL/FRAME:020962/0137 Effective date: 20080430 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |